OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2020-12-31-accounts

Children with Cancer UK

Trustees’ Report and Financial Statements for the year ended 31 December 2020

Registered Charity Number: 298405 Inaugurated by Diana, Princess of Wales Company limited by guarantee, Number: 4960054

Financial Statements For the year ended 31 December 2020

Children with Cancer UK in numbers

Research - We’re committed to finding cures and kinder treatments for children and young people with cancer

£6M

invested into vital, life-saving research

24

new research awards

2

Clinical PhD studentships funded

Supporting families – We help children with cancer and their families through the hardships of a cancer diagnosis

240

families attended our new format virtual events

£1m

to Teenage Cancer Trust for the provision of frontline services during the COVID-19 pandemic

£285K

towards Beads of Courage UK

Awareness – We shine a spotlight on the impact of cancer on children and young people and their families

827K

people have interacted with us on social media

1.1Bn

media reach

96

letters issued to parliamentarians as part of Childhood Cancer Awareness Month

16 families told their childhood cancer stories through our channels

2

Financial Statements For the year ended 31 December 2020

CHILDREN WITH CANCER UK

TRUSTEES’ ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

Olivia, pictured on the front cover, ringing the end of treatment bell

3

Financial Statements For the year ended 31 December 2020

TRUSTEES’ ANNUAL REPORT

MESSAGE FROM THE FOUNDER AND CHAIR OF 05 – 06
CHILDREN WITH CANCER UK
OUTCOMES IN 2020 07
RESEARCH OUTCOMES IN 2020 08 – 13
SUPPORTING FAMILIES IN 2020 14 – 17
AWARENESS ACTIVITIES IN 2020 18 – 21
FUNDRAISING 22 – 28
THANK YOU 29
FINANCIAL REVIEW 31 – 32
STRATEGIC PLANS 33 – 37
GOING CONERN, RISKS & GOVERNANCE 38 – 45
REFERENCE AND ADMINISTRATION 46 – 47
STATEMENT OF TRUSTEES’ RESPONSIBILITIES 48
INDEPENDENT AUDITORS’ REPORT 49 – 52
CONSOLIDATED FINANCIAL STATEMENTS 53 – 55
NOTES TO THE FINANCIAL STATEMENTS 56 – 74

4

Financial Statements For the year ended 31 December 2020

MESSAGE FROM THE FOUNDER AND CHAIR OF CHILDREN WITH CANCER UK

Welcome to our Annual Report and Accounts for 2020.

An unprecedented year due to COVID

I write to you as the country is emerging from further lockdowns. 2020 was an unprecedented year where we have all had to deal in our own ways with the COVID-19 pandemic. I am sure some of our supporters may have suffered personal losses and I would like to extend my heartfelt condolences to you and your families. Family is at the heart of Children with Cancer UK as I set up this charity, having lost two of my children to cancer within nine months of each other in 1987.

Unfortunately COVID-19 has had a huge impact on all aspects of our lives and childhood cancer research has not been exempt from this. In June 2020, the Association of Medical Research Charities (AMRC) projected an average 41% decrease in their medical research spend over the next year, leaving a £310 million shortfall. Their research estimated it would take approximately 4.5 years for charity funded medical research spend to recover to normal levels. Sadly, with childhood cancer survival rates showing little in the way of improvement, this delay in breakthroughs and development of new treatments simply isn’t acceptable.

As one of the leading UK funders of childhood and young adult cancers we have been very aware that a drop in our income would be hard felt in the child/young adult cancer research community. In particular, our charity focuses on funding basic and preclinical research, which is necessary to bring new treatments for these rare diseases to the point where they are ready for clinical trials. Despite a drop in income in 2020 I am delighted to tell you that we have managed to avoid cutting any existing or ongoing grants.

In 2020 we funded new research grants, as planned, worth £3.3 million through our Treatment and Survival funding call. These research projects will seek better and more effective treatments for childhood cancer. One of our aims is to reduce the long term side effects that many survivors are left with and we are dedicated to helping improve their quality of life after they have rung the end of treatment bell. We also continue to prioritise those cancers that face the poorest outcomes, with more than £1 million spent on brain tumour research and around £400,000 allocated towards osteosarcoma research in 2020.

We embarked on an important new collaboration with Cancer Research UK as we have co-funded new innovative research projects to transform our understanding of children’s and young people’s cancers and find new ways to prevent and treat these complex cancers. By committing £2.5 million and Cancer Research UK matching our award to create a £5 million Innovation Award programme we ensured that even during such uncertain times our commitment to fund medical research continues. Joining forces allows us to invest more in this field and to engage and unite a broader network of childhood cancer expertise.

We were also able to provide £1 million to Teenage Cancer Trust in 2020 for the provision of frontline services during the COVID-19 pandemic. Teenage Cancer Trust specialises in nursing and emotional support for vulnerable teenagers and young people to improve their experience, survival and recovery from cancer. During the COVID-19 pandemic young cancer patients have faced a tough time with even more isolation and uncertainty with many health services stretched beyond their limits. Our funding meant that Teenage Cancer Trust could continue to offer their services during this incredibly worrying time.

5

Financial Statements For the year ended 31 December 2020

Unfortunately, it’s not all positive news that I will share from 2020 as our fundraising has been hit very hard by COVID-19. We have been faced with a 26% drop in our income and we are realistically expecting that it will take us a number of years to return to pre-pandemic levels of fundraising. This is mainly due to the cancellation of events and opportunities for meeting with our supporters face to face such as the Virgin Money London Marathon, which has always been a highlight in our calendar. Our strategy now is to build on the areas where we can see opportunities for growth by seeking new growth and attracting new calling on our dedicated corporate, Trust and philanthropic supporters.

It’s so important for us to continue striving towards a world where no child dies of cancer. Sadly, there are still too many children diagnosed with cancer each year and being subjected to incredibly harsh treatments. Together, we must provide hope through targeted and specialist cancer research.

Although we are still very much in the midst of the pandemic, I am optimistic about the coming years and the future of this charity. I’d like to say a personal thank you to all our loyal supporters who have seen us through the most difficult period in our 33 year history. It means a great deal that you share our vision and thanks to you, we are able to continue funding life-saving research and essential support services for children with cancer and their families.

Eddie O’Gorman OBE

Founder and Chair of Trustees

6

Financial Statements For the year ended 31 December 2020

OUTCOMES IN 2020

How donations have helped children and young people with cancer.

We are pleased to announce that in 2020 we raised £13.7m to fund specialist childhood cancer research and support families.

For every £1 we spend on fundraising, we raised £7 more

For every £1 donated we spend

We receive no government funding and rely exclusively on the generosity of our supporters

7

Financial Statements For the year ended 31 December 2020

OUR YEAR IN RESEARCH

Research is integral to driving forward our vision of a world where every child survives cancer. Only around 2% of cancer research funding in the UK is spent on research that is fully dedicated to childhood and young adult cancer. Children with Cancer UK plays a major role in funding vital life-saving research solely dedicated to childhood cancer - research that would otherwise go unfunded. We invest in specialist research to gain new insights into the genetic and environmental causes of cancer and improve the diagnosis, treatment and long-term care of children with cancer.

In 2020 we funded 24 new research grants, worth over £3.5 million into childhood, teenage and young adult cancer. These grants focus on projects that aim to discover and develop kinder and more effective treatments and improve the long-term health outcomes for children, teenager and young adults diagnosed with cancer.

Combined with existing active research grants, this means that we are now funding a total of 83 projects, worth over £21 million across the UK and abroad. Our funding is helping more children survive cancer and look forward to longer and healthier lives after their treatment has ended.

The COVID-19 pandemic had a significant impact on research within the UK in 2020 and it continues to be a challenging time for our funded researchers. Many researchers with clinical expertise had to pause their work to return to the NHS frontline where they helped hospitals overwhelmed by coronavirus cases. Meanwhile, some of our other researchers faced long laboratory closures or restricted laboratory access due to social distancing measures. Children with Cancer UK has been able to support our researchers during this time by allowing flexible working patterns and awarding extensions to those projects that were unavoidably delayed. With this support, most research projects were able to continue and make progress.

Cancer Research UK–Children with Cancer UK Innovation Awards

In 2020 Children with Cancer UK joined forces with Cancer Research UK to co-fund five new, innovative research projects to transform our understanding of children’s and young people’s cancers and find new ways to prevent and treat these complex cancers. Children with Cancer UK contributed £2.5m to the Awards with Cancer Research UK matching this value.

As two of the biggest independent funders of children’s and young people’s cancer research in the UK, working together allows us to fund more research into these cancers and accelerate our progress to improve survival.

Co-funded by Cancer Research UK and Children with Cancer UK, five teams of scientists who are leaders in their field have been awarded up to £1 million each to delve into the biology of children’s and young people’s cancers. At the time of writing funding for these projects comes in at £4.3 million in total, equally funded by Children with Cancer UK and Cancer Research UK.

8

Financial Statements For the year ended 31 December 2020

The Cancer Research UK–Children with Cancer UK Innovation Awards will allow researchers to gain a better understanding of cancer in children, which they hope will lead to the development of better and less toxic treatments.

New research awards

In 2020 we funded 16 new research grants worth £3.3 million through our Treatment and Survival funding call. This grant call sought to fund research to address improved treatment for and survival from childhood and young person cancer and to improve the quality of ongoing life.

We continue to prioritise those cancers that face the poorest outcomes, with more than £1 million allocated towards brain tumour research and around £400,000 allocated towards osteosarcoma research in this call. We also awarded two Clinical PhD Studentships, which are designed to build capacity and bridge the gap between research and clinical practice, so new discoveries can reach and benefit patients sooner.

All applications to our research funding calls are rigorously scrutinised by our independent Scientific Advisory Panel and reinforced by expert peer review to the standards set by the Association of Medical Research Charities. This ensures that we only support the highest quality research that will have the greatest impact in terms of patient care.

In addition, Children with Cancer UK teamed with the International Agency for Research on Cancer (IARC), which is part of the World Health Organisation (WHO), to fund research projects under a Postdoctoral Fellowship scheme. These Fellowships are designed to develop and support future leaders in cancer research with an international focus.

Here is an overview of some of the projects we funded in 2020.

Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma, Professor Chris Jones, Institute of Cancer Research

Diffuse Midline Gliomas (DMGs) are aggressive childhood brain tumours, which include diffuse intrinsic pontine gliomas (DIPG). There is currently no cure. A class of cancer drugs, called MEK inhibitors, have shown early promise in treating some DMGs but there is a risk that these tumours could develop resistance to these drugs.

9

Financial Statements For the year ended 31 December 2020

MEK inhibitors, are currently being tested in children with low-grade gliomas, raising optimism for a therapeutic strategy that can be readily translated to DMGs. Prof. Chris Jones and his team have developed laboratory models of DMGs using cells taken from patients with these tumours and found that MEK inhibitors may act as effective treatments in some cases. However, MEK inhibitors have been found to have limitations when used to treat other types of cancer. In other tumours, MEK inhibitors can quickly stop working as the cancerous cells develop resistance by a variety of mechanisms. To date, this has not been explored in DMG. Prof. Jones and his team aim to work out the mechanisms by which DMG cells become resistant to MEK inhibitors and come up with new combinations treatments to overcome this.

The study team have unique resources of patient DMG tumour samples from their ongoing BIOMEDE clinical trial in children and young people. They will treat the cells with MEK inhibitors and find out which ones survive the drug, and how they have managed to become resistant to the drug. Prof. Jones and his team will also carry out large-scale drug-treatment experiments where they ‘delete’ every gene present in the tumour cells one-by-one and find out which combination of drug and gene ‘knock-outs’ causes the cells to die. From these ‘hits’ they will develop combined drug treatments to test in the laboratory models, and hopefully overcome the resistance that can develop when using MEK inhibitors alone.

Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL), Dr Marc Mansour, UCL Cancer Institute

T-cell acute lymphoblastic leukaemia (T-ALL) is a type of childhood leukaemia caused by the body overproducing T cells, a type of white blood cell. It is rarer but more aggressive than B-cell acute lymphoblastic leukaemia (B-ALL), does not always respond to chemotherapy and has very few treatment options when the disease relapses.

CAR T-cell therapy is an exciting new type of cancer treatment. It works by instructing healthy T cells from the body’s immune system to attack cancer cells that display a particular molecule on their surface. Unfortunately, there isn’t a CAR-T cell therapy for T-ALL, which is more difficult to treat this way.

Dr Marc Mansour and his team have identified a protein that appears to be present in high quantities on the surface of T-ALL cells, but not on healthy T-cells. In this project, Dr Mansour and his team will first investigate exactly how much protein is present on different types of T-ALL cells and at different stages of the disease. They will then check that this protein isn’t present on any of the cells in important organs in the body, otherwise targeting it could have dangerous side effects. Once this is confirmed they will develop CAR T-cells capable of recognising and targeting the protein and test how effective they are in pre-clinical models.

This project hopes to produce the first CAR T-cells that can safely kill T-ALL cells without also harming healthy cells. If successful, Dr Mansour and his team will next work towards developing a clinical trial for this new treatment in relapsed and hard-to-treat T-ALL.

10

Financial Statements For the year ended 31 December 2020

Investigating the long-term health impacts of surviving childhood cancer, Dr Defne Saatci, University of Oxford

As treatments continue to improve, more children are outliving their cancer into adulthood. Unfortunately, surviving childhood cancer can come with significant long-term health and social complications, which are still poorly understood.

Previous studies have helped to identify several long-term health complications faced by childhood cancer survivors. These studies, however, have not been able to paint a complete picture in our understanding on a range of these complications, including the impact on mental health, fertility, and school performance. This is because these studies either only looked at a small number of children or are missing important details about the patient journey and more recent cancer treatments children receive. This means there is still a significant gap in our understanding of these late effects of childhood cancer. There is a pressing need to understand why these long-term health complications arise and to develop appropriate clinical services and implement policy changes.

Dr Defne Saatci’s project aims to better understand these long-term health impacts of childhood cancer by conducting a detailed UK-wide population investigation to overcome the limitations of previous studies. She will be using QResearch Database, the largest national primary care database linked to several other key national databases, including Hospital Episode Statistics and the National Cancer Registry.

By taking advantage of these linked national databases, Dr Saatci and her team aim to build a more comprehensive picture of these long-term health impacts faced by childhood cancer survivors in the UK. Her research is funded under the Children with Cancer UK’s Clinical PhD Studentship scheme, which is provided to develop and support future leaders in clinical cancer research.

11

Financial Statements For the year ended 31 December 2020

Cancer Research UK–Children with Cancer UK Innovation Awards – a turbo-boost for research into children’s and young people’s cancer

The five teams being funded through the Innovation Awards will be looking at:

1. Understanding why some children inherit a greater risk of developing cancer

Professor Richard Houlston at The Institute of Cancer Research, London, will lead a team to identify previously unknown inherited gene mutations that increase a child’s chances of getting cancer. This work could determine new ways to monitor children with these mutations, allowing doctors to diagnose cancer sooner and to better tailor each child’s treatment and care.

2. Understanding why chromosome duplication occurs in the cells of children with cancer, and if it can be used when designing new treatments

Professors Christine Harrison, Jonathan Higgins and Steve Clifford at Newcastle University will lead a team investigating a phenomenon where cancer cells of children and young people gain chromosomes, known as aneuploidy. This is found in many types of childhood cancers, and by understanding why this happens, they hope to find new ways to prevent and treat them.

3. Developing a new way to treat a type of acute lymphoblastic leukaemia (ALL) using the immune system

A form of ALL known as Mixed Lineage Leukaemia (MLL) gene rearranged infant ALL (MLLr-iALL) has poor survival. CAR T-cell therapy, which uses modified versions of a patient’s T cells to attack their cancer, is often used to treat leukaemia. But using this potentially life-saving treatment in very young patients is limited. This is because it’s very difficult to obtain T cells from them, as these patients have already gone through intensive chemotherapy and are often immunocompromised. Dr Anindita Roy at the University of Oxford, and Professor Anastasios Karadimitris of Imperial College London, plan to test a new way of treating the disease by adapting this therapy to use a different type of immune cell called invariant natural killer T (iNKT) cells that can be taken ‘off the shelf’. They hope this CAR-iNKT cell therapy will be a more effective way of treating these very young patients.

12

Financial Statements For the year ended 31 December 2020

4. Improving outcomes for children and young people whose ALL relapses after treatment

Survival for children and young people with ALL is high, but the outlook is poor if treatment doesn’t work and the cancer comes back. Professor Marc Mansour, Dr David O’Connor, Dr Jack Bartram and Professor Owen Williams of University College London and Great Ormond Street Hospital for Children are investigating the causes behind ALL coming back, which has been historically difficult because relapse is rare. By establishing a nationwide study, the team hope to develop new ways of treating relapsed patients and predicting which patients will respond to each therapy.

5. Identifying new targets to treat rhabdomyosarcoma (RMS), a skeletal muscle cancer, by investigating its foetal origins

The biology of RMS is largely unexplored, but is thought to originate from cells in the foetus that develop incorrectly. Some of these cells persist in children with RMS when usually they wouldn’t. Dr Sam Behjati at the Wellcome Sanger Institute, and Dr Karin Straathof at University College London, want to understand why this happens by building a cell ‘atlas’ – a complete guide to the cells that form RMS. They hope that understanding how RMS develops will help bring to light new targets for treatment.

Bone Cancer Awareness Initiative - A new life-saving collaboration

To mark the start of Sarcoma Awareness Month in July 2020, Children with Cancer UK and the Bone Cancer Research Trust announced their second collaborative project – the Bone Cancer Awareness Initiative. Primary bone cancer is a devastating rare form of cancer, affecting around 560 children, teenagers and adults each year in the UK. For decades patients have reported experiences of late diagnosis and progressed disease by the time a diagnosis has been made. This dramatically reduces survival, increases the need for life-changing surgery and treatment and significantly reduces post-treatment quality of life. Medical professionals, including General Practitioners, receive no dedicated training on the signs and symptoms of the disease, despite 10-year survival rates being little over 50%.

To tackle this problem, The Bone Cancer Awareness Initiative developed free educational resources for medical professionals as part of its 100-day online and postal campaign. The initiative reached out to GP practices, medical students, radiology departments, muscular skeletal physiotherapists, and pharmacies in the UK. It provided them with free medical resources tailored for each discipline, including posters and flashcards that explained the presenting symptoms, radiological features and referral pathways for primary bone cancers and tumours. For the first time, this campaign provided them with the knowledge and tailored tools to identify a potential case of primary bone cancer and provided guidance on how to confirm or rule out a diagnosis. In total over 25,000 information packs were posted to healthcare professionals across the UK. By increasing awareness and understanding we can increase speed of diagnosis, improve outcomes and save lives.

13

Financial Statements For the year ended 31 December 2020

SUPPORTING FAMILIES IN 2020

We funded £1,285,296 towards projects aimed at alleviating some of the burdens a cancer diagnosis places on children with cancer and their families. We also hosted 240 families at 10 events throughout the year, giving them happy memories and a welcome respite from the daily worries cancer brings.

Vital support for frontline services during the COVID-19 pandemic

During 2020 we were able to provide £1 million to Teenage Cancer Trust in 2020 for the provision of frontline services during the COVID-19 pandemic. Children with Cancer UK is proud to have supported Teenage Cancer Trust’s crucial frontline services during this particularly challenging time.

Teenage Cancer Trust is the only UK charity specialising in nursing and emotional support for vulnerable teenagers and young people to improve their experience, survival and recovery from cancer. They work with the NHS to provide age-appropriate hospital wards and specialist care services. Teenage Cancer Trust’s frontline staff support almost 79% of young people who are newly diagnosed with cancer, and many more as they continue their treatment or need support after their treatment has ended. They also support the young patients’ family and friends, to help them cope and to support each other.

During the COVID-19 pandemic, these young patients have been going through the toughest times they may have faced, with even greater uncertainty and isolation than ever before, and healthcare services becoming incredibly stretched. Many patients are particularly at risk from COVID-19 and have been forced to shield, and many found that their treatments and check-ups were delayed or cancelled due to the pandemic.

Teenage Cancer Trust had to quickly adapt to keep young people and themselves safe from the Coronavirus. While COVID-19 cases rapidly increased across the country, hospitals had to alter the way they operate to facilitate the volume of patients. This has meant that some of the hospital wards have had to change the way they support young people with cancer.

Vital funding provided by Children with Cancer UK meant that Teenage Cancer Trust could continue to provide support to young people during this time. These services included providing specialist nurses, Youth Support Coordinators and facilities management. They also included the development and management of online support for patients, including an online community, advice hub and virtual events. Together, these services helped to make sure young people with cancer did not face this crisis alone and continued to receive the best treatment, care and support.

14

Financial Statements For the year ended 31 December 2020

Beading helps healing

In 2020 we continued our partnership with Beads of Courage UK and committed to funding the Beads of Courage Oncology Programme for a further three years.

The programme promotes positive coping strategies by helping children to visualise and articulate their experiences through a process called beading. Different beads are given to children to represent and record each step of their treatment. The hope, support and encouragement given to children with this positive reinforcement tool, whilst going through cancer treatment enables families and children to come to terms with the many treatments and protocols on their journey. Children are able to own, record and then show and tell others the courage they faced during treatment.

In 2020, three new beads were introduced to the programme, expanding the reach and support given to children. These beads represent different types of therapeutic support children receive through their cancer journey:

15

Financial Statements For the year ended 31 December 2020

Amazing days out for families affected by childhood cancer

A snapshot of our much-loved events that allow families to enjoy quality time together and a break from the daily stresses of a childhood cancer diagnosis.

COVID-19 restrictions resulted in us having to cancel all our amazing days out. Not being able to physically meet up didn’t stop us from putting on amazing days in for children with cancer and their families. Instead we adapted to the changing environment and hosted the following virtual parties.

Pirate and Fairy Virtual Party

On Wednesday 27 May 2020, we held two virtual parties for children affected by cancer, hosted by Fairy Sparkles and Pirate Pete.

These parties kept children entertained with dancing, magic and games, including a scavenger hunt around the house, allowing the children to forget about lockdown, COVID-19 and cancer for a little while.

Harry Potters Birthday Virtual Party

We celebrated Harry Potter’s birthday in July by putting on a virtual party for 50 children impacted by cancer. The party was hosted by Harry Potter and the children were kept entertained with dancing, magic, and they tested their wizarding knowledge in a Harry Potter quiz. The children dressed up for the occasion in their finest Hogwarts gear and submitted their photos for a costume competition.

Harry Potter stars, Bonnie Wright (Ginny Weasley), Evanna Lynch (Luna Lovegood) and Matthew Lewis (Neville Longbottom) all sent special video messages, wishing the children a magical time at Harry’s birthday party.

Super Science Virtual Party

In September we hosted an interactive virtual Science Party with Einstein Entertainers. 70 families signed up to join the virtual party lasting 45 minutes, to play party games and get involved in fun scientific experiments. A few of the experiments included bubble cannon, slime making and helicopter making. All of the children received a mini home lab kit in the post which had everything they needed to take part in the experiments and get involved in the fun.

“Gwen really enjoyed the party. She has had a tough weekend after lots of seizures, so it really helped us. Gwen’s been talking about how much she loves science and wants to be a scientist ever since” – Mahoney, Gwen’s dad

16

Financial Statements For the year ended 31 December 2020

Halloween Craft Virtual Party

In October, we sent out 80 craft kits to families to have their own crafty afternoon during the half term. They created Lanterns, Keyrings and bookmarks with a YouTube link provided by Made by Me Parties.

Christmas Virtual Welfare Activities

We wanted to bring some magic and Christmas cheer into the homes of families affected by childhood cancer. Unfortunately, our usual Christmas parties were unable to go ahead, but we still had lots of festive fun for families to get involved in.

We held a virtual Christmas Craft Party on 13th December and over 90 families received their craft kit in the post beforehand ready for the crafty fun! The children made a beaded snowflake decoration, an LED snowman decoration and they also decorated their own fabric stocking. Our Virtual Christmas Party, held on 21st December, was hosted by Captain Fantastic and saw 65 families get involved with games, dancing and some exciting challenges.

“Seb had a wonderful time at the party. He laughed so much he nearly fell off his chair. It was so interactive and simple to follow. Thank you for all your amazing events and bringing so much joy to our family during these hard times.” Natasha, Seb’s mum.

We temporarily transformed our office into a COVID secure Santa’s workshop and packed and posted 180 gift boxes for families affected by childhood cancer. These gift boxes included sweet treats, baking kits and games to play with the whole family!

Finally, Christmas wouldn’t be complete without Santa. We gave families the opportunity to sign up to receive a personalised video message from Santa, recorded all the way from the North Pole! One of the messages was for Beatrix, age 4, and Santa gave her a special well done for finishing her chemotherapy in November and ringing the end of the treatment bell.

“This is phenomenal. The girls absolutely loved it. Their faces were a picture. So incredibly special given Beatrix has her port removal operation in 4 days and we’re shielding at home in preparation. They loved the special mention with their names in. It got even the 9 year old to still ‘believe’.” Lin-Marie, Beatrix’s mum

17

Financial Statements For the year ended 31 December 2020

RAISING AWARENESS OF CHILDHOOD CANCER DURING THE COVID-19 PANDEMIC

We began 2020 with clear objectives of raising awareness of childhood cancer and building our audience of supporters, but within a few months the world was changing as we entered the COVID-19 crisis. When the country went into national lockdown it was clear that our plans would have to change rapidly. Overnight we had to adapt to digital only communication between all our teams as we would be working from home for the foreseeable future.

It was estimated that our income was at risk due to the cancellation and postponement of our fundraising events. This would place significant limitations on the amount of life-saving research and support we would be able to fund. The charity had to adapt very quickly to maximise our digital donations in lieu of any face-to-face opportunities we had relied on in previous years. The varying degrees of lockdown that we encountered regionally and nationally provided us with an opportunity to engage with more people digitally as most people were spending time at home watching more television and consuming more content online.

We decided it was more important than ever to keep communicating with our target audiences and supporters via digital channels. We needed to keep our supporters up to speed with what we’re doing and how we will continue to provide hope to families affected by childhood cancer. We also needed to continue reaching new audiences and building our supporter base for the future.

How our digital channels performed and adapted to COVID-19

We looked at ways of increasing our digital revenue through the website by:

We produced content about COVID-19

18

Financial Statements For the year ended 31 December 2020

Overall digital performance in 2020

Our website

Midway through 2020, we successfully restructured and launched our new improved website. The restructure helped make navigating through the website a lot easier for people visiting our website.

The restructure allowed us:

We also constantly test and optimise our website to give our supporters the best possible experience. It is this work that has contributed to more donations being received through our website in 2020 than in any previous years.

Making our voice heard

19

Financial Statements For the year ended 31 December 2020

Raising our profile with MPs and key influencers in Westminster

In 2020 we set out to establish a political engagement programme to help to drive childhood cancer up the political agenda, highlight the need for increased research funding and promote the AMRC’s ask for a life sciences charity partnership fund. In light of the COVID-19 pandemic, we needed to make decision makers aware that our research funding was under threat and this would result in delays to discoveries and improvements in treatment.

We managed a political engagement programme that helped to drive childhood cancer up the political agenda and with the aim of increasing research funding. We were calling upon Government to see the following action:

As part of our engagement we sent letters to the following MPs who held the following position at the time of writing to them:

This led to meetings with:

Neale Hanvey MP spoke at a Debate in the House of Commons on 24[th] November 2020 where he called on the Government to provide at least £310 million in funding in the financial year 2021 to a life sciences charity partnership fund, to secure medical research for the next three years, thus preserving research charities’ vital and unique contribution to society and to the economy. He proposed that this would be matched by funding from charities to secure the continuity of their research. In his role as Chair of the Health Select Committee, Jeremy Hunt MP sent a letter to the Treasury on behalf of the charity as did Committee Member Dr James Davies MP.

20

Financial Statements For the year ended 31 December 2020

We also issued a letter to 96 parliamentarians ahead of Childhood Cancer Awareness month in September to make them aware of our campaign and policy asks. This led to some engagement on social media from Members of Parliament.

Telling the story of childhood cancer

We are so grateful to all the families affected by a childhood cancer diagnosis who choose to share their story. It’s such an important element of how we are able to raise awareness of the realities of being diagnosed and treated for childhood cancer. It also helps us to demonstrate the issues that need addressing and are so generously funded through our supporters.

Thank you to the 16 new families who told their story in 2020 and welcome to the Children with Cancer UK family:

Ethan, Izzy, Alice, Mia, Astrid, Ceylian, Gaspard, Lewis, Emmy, Isla-Mae, Sholto, Jessica, Tattianah, Thomas, Eve and Teddie

21

Financial Statements For the year ended 31 December 2020

FUNDRAISING HIGHLIGHTS

Our greatest fundraising achievements in 2020, that have helped more children with cancer ring the end of treatment bell, include:

22

Financial Statements For the year ended 31 December 2020

Corporate

COVID-19 had an extreme impact on the corporate partnerships team’s ability to fundraise this year as the majority of our partnerships raise funds through employee fundraising. We were still able to leverage the two most productive fundraising months of the year for Children with Cancer UK (Childhood Cancer Awareness Month in September and Christmas in December) to engage our current and new partners in fundraising activations.

Childhood Cancer Awareness Month – Unilver - Zendium

During Childhood Cancer Awareness Month we partnered with Zendium toothpaste, a brand of Unilever, which resulted in £15,000 in donations from online sales of the toothpaste from the Zendium shop, Amazon and views of the YouTube video. The activity also created greater awareness of Children with Cancer UK with 4.5 million impressions of social media posts and increased traffic to our website.

Christmas - Ladbrokes

We received a donation of £38,841 from Ladbrokes post our Christmas fundraising campaign.The funds were generated form employee fundraising which was an amazing achievement considering all of their shops were closed and 90% of employees were on furlough. We worked with the Ladbrokes retail leadership team to launch an engagement activity over Christmas for retail employees to get involved.

Entitled The 12 Days of Christmas, employees were encouraged to get involved with daily challenges and messages of goodwill. Daily challenges included competing for the title of “Best Dressed Christmas Tree”, “Best Christmas Pet” and “Best Elf on a Shelf” to name a few by sending in photos to the Retail Communications Team. To kick start the event, the senior retail operations team created a video, The 12 Days of Lockdown, using the familiar 12 Days of Christmas tune but with changed lyrics reflecting everything that had happened in 2020.

Kwik Fit

Children with Cancer UK were selected as Kwik Fit’s first ever charity of the year following a vote open to more than 5,000 Kwik Fit employees across the UK. The partnership which ran throughout 2019 ended in June 2020. Thanks to Kwik Fit’s hard work and dedication they raised £1.07 million. This donation will be used to purchase a NovaSeq 6000 high-throughput DNA sequencing machine for Birmingham Women’s and Children’s Hospitals Trust, annual maintenance costs for five years and additional IT storage capacity, and will contribute towards the necessary estate costs.

Committed givers

Economic uncertainty and the shift in time spent at home with the pandemic has seen a significant benefit of recruiting supporters through TV advertisements for us and will remain a priority area. We significantly exceeded targets for TV advertisements due to a combination of new ‘locked down’ audiences and lower media rates. The 1 year return on investment was the highest we’ve ever seen. The Christmas adverts in particular performed exceptionally, and we received over double the expected number of responses to the TV adverts (29.8k compared to forecast of 14.9k).

23

Financial Statements For the year ended 31 December 2020

Playing to win and to help more children with cancer

Increase in gaming activity is often a trend in times of economic uncertainty and has been seen across the charity sector. Both our cash and raffle appeals exceeded our year on year targets, with particular growth in raffle appeal income. In 2020, we recruited over 2.6k new weekly lottery players which is nearly 3 times the number recruited in 2019. This is largely due to the success of our lottery TV advert. Before the first lockdown, we also found success in our small-scale testing of face to face lottery recruitment at supermarkets and Poundlands, we hope to build on this in 2021.

Future focus: Stewardship and legacies

COVID-19 saw our legacy event programme cancelled, but throughout the year we continued to look at opportunities to engage supporters giving gifts in their Wills. We ran our first external digital promotion of our Free Wills service that integrated with our Christmas activities. 2020 has seen our highest legacy income of over £2.1 million and this area remains a key opportunity for us to continue to develop and grow.

Stewardship of our supporters and potential legators has remained a priority and our new biannual newsletter, ‘The Chime’, has seen significant engagement. Results have benefitted from the limitations on activity in lockdown and this provides promising indications of our supporters’ ongoing engagement with our work.

Digital enhancement of campaigns

2020 saw the launch of three new microsites; for our gaming products, which have significantly improved results for both our Grand Draws and weekly lottery, and our new ‘Remembering’ in memory tribute site, which is performing well since its launch in September having raised nearly £15k and will continue to grow with greater promotion in 2021.

Virgin Money London Marathon

2020 began well with 1274 runners registered to take part in the Virgin Money London Marathon on 26th April for Children with Cancer UK. Due to COVID-19 the 2020 Virgin Money London Marathon was postponed until October and eventually cancelled with a virtual event taking place instead.

On Sunday 4th October, we had a team of over 800 runners, across the world, including staff members of the charity, taking to their streets locally to complete 26.2 miles within 24 hours. The Virtual Virgin Money London Marathon had a total of 37,966 finishers meaning it was awarded an official Guinness World Records title for the ‘Most users to run a remote marathon in 24 hours.

In 2020 we raised over £1.4m from the Virgin Money London Marathon. The runners who were due to take part in the physical 2020 Virgin Money London Marathon have been able to defer their place to the 2021, 2022 or 2023 London Marathon.

24

Financial Statements For the year ended 31 December 2020

The Children with Cancer UK Ball

The Children with Cancer UK Ball is one of the highlights of our event calendar, with expected income of over £700k. 2020 would have marked the 33rd year of The Children with Cancer UK Ball. We should have welcomed over 800 guests for an evening of spectacular entertainment and fundraising at The Grosvenor House Hotel in London. Unfortunately, due to COVID-19 restrictions, the 2020 Ball was cancelled. Due to continued uncertainty, we are not due to welcome this event back until 2022.

Event cancellations

Due to COVID-19 restrictions the majority of our Sports and Special Events were unfortunately cancelled or postponed. This has had a massive impact on the charity and resulted in a 67% decrease in income from 2019 to 2020 across these fundraising streams. We have started to bring back these Sports and Special events tentatively with smaller audiences during 2021, with a plan to build up to our usual event calendar in 2022. A Golf event and Swim Serpentine being held during the summer of 2021 is encouraging evidence that these events can return in 2022.

Mini Superhero Challenge

The Mini Superhero Challenge is a Children with Cancer UK event originally aimed at schools and youth groups to take on a challenge of their choice revolving around the number 12. In light of the COVID-19 pandemic, together with knowing that even during the pandemic 12 children and young people would still continue to be diagnosed with cancer every day in the UK, the Mini Superhero Challenge was adapted to enable individual children to get involved from the comfort of their own homes. By encouraging children to take on a challenge of their choosing (such as Mini Superhero Chores for Change or the Mini Superhero Mile a Day March), the event saw 249 people taking part including Karley Ward’s two children, Evie and Tommy, who fundraised in memory of their baby sister Isobelle and raised over £11k by doing the washing at home for 12 days. It is thanks to Evie and Tommy and all of the amazing children who took part that helped raise over £30k and we would like thank everyone for their wonderful support.

The Georgia Morris Fund

The Georgia Morris Fund was set up in 2017 after Richard Morris lost his daughter Georgia to Neuroblastoma in October 2016. They have been fundraising ever since, choosing to split the funds between Children with Cancer UK and Neuroblastoma UK. They were fortunate enough to be able to host their annual fundraising Charity Dinner a week before the national lockdown was imposed and raised a fantastic £14.5k. Children with Cancer UK would like to wholeheartedly thank them for all their incredible dedication and ongoing support in Georgia’s memory.

25

Financial Statements For the year ended 31 December 2020

Tizzard Racing Limited

Tizzard Racing Limited kindly chose to support Children with Cancer UK and Target Ovarian Cancer by fundraising in memory of Kim Gingell, who passed away in May this year from a short battle with cancer. With the support of Freddie, Dave, Joe, Richard, Glen, Kat and Joanna, Tizzard Racing Limited completed a 226 mile cycle ride from Lower Zeals to Lands End. By following national COVID-19 rules and guidance around outdoor events, the team raised £18.5k for Children with Cancer UK. We would like to say a huge thank you to everyone who took part and to Tizzard Racing Limited for their incredible donation and support in memory of Kim.

Finnley’s Warrior’s

Finnley’s Warrior’s was set up in 2017 by Finnley’s parents, Ali and Donna, after Finnley was diagnosed with a rare and aggressive form of cancer, Anaplastic Large Cell Lymphoma at 16 months old. During the COVID-19 pandemic their fundraising didn’t stop and they decided to adapt and take advantage of the situation by holding a summer fundraising event which they wouldn’t usually hold. They also set up a virtual event, ‘Wrap Our Arms Around the World Challenge’. This saw over 250 people take part in the physical team challenge, together circumnavigating the earth by running, cycling or walking and raising £5.4k. We are so grateful to everyone who took part in this challenge and to Ali, Donna, Finnley (and new arrival Rosie), for their incredible dedication and ongoing support.

26

Financial Statements For the year ended 31 December 2020

FUNDRAISING COMPLIANCE

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.

We will keep the donor’s personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor’s details with other charities or sell it to businesses. Some organisations help us with our fundraising, but will only use the donor’s data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (updated February 2020).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Protecture, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes: call monitoring, site visits and live call listening and mystery shopping. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerately disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to the protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document ‘Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.’

We adhere to the Fundraising Regulator Promise ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters, which is why, in 2018, we published our Supporter Charter as a commitment to our supporters.

27

Financial Statements For the year ended 31 December 2020

Our Feedback and Complaints policy was reviewed in February 2020 and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan – Dec) 2020 we received 248 complaints across all teams which is an increase on the previous year (162 complaints). The majority of these complaints relate to clothing collections that take place through a third party and this is to be expected for this type of activity.

We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards and we will work hard to learn from our mistakes and to make sure they don’t happen again. If our supporters and members of the public are unhappy with any aspect of our work we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.

COVID-19 has had an impact on the way Supporter Care work. We have been very fortunate that a staff member lives close by and has been able to walk to the office. This has meant that we have not had to set up a redirection on post, as some charities have done, and that all money is batched on site. We have been able to use technology to help us communicate with supporters by phone through our laptops as usual. In future we feel the Supporter Care Team will be able to work from home and from the office which gives the team a better work/life balance.

28

Financial Statements For the year ended 31 December 2020

THANK YOU

A massive thank you to all our supporters and fundraisers, who despite the pandemic, helped us raise an incredible £13.5m in such a difficult year.

To our corporate partners:

To everyone who continued to support Children with Cancer UK’s fundraising efforts:

To our dedicated Trustees:

All our supporters and volunteers have helped improved the lives of children with cancer and their families – thank you.

A very special thank you goes to all the extraordinary families who have shared their experiences in 2020. Your involvement is central to our work and your help in raising awareness and vital funds to help young cancer patients is invaluable.

29

Financial Statements For the year ended 31 December 2020

FINANCIAL REVIEW

Incorporating the Directors’ Strategic Report and Administrative Report for Companies Act Purposes

30

Financial Statements For the year ended 31 December 2020

The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31[st] December 2020 under the Charities Act 2011 and the Companies Act 2006, including the Directors’ Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

Financial review

The Consolidated Statement of Financial Activities (SOFA) set out on page 51, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

Our total income has fallen this year from £17.3 million to £13.7 million. The fall of almost £4 million is due to the impact of the COVID-19 pandemic on our fundraising operations. The London Marathon has historically been an important fundraising event for us with a large presence of runners raising a significant amount of sponsorship income. The absence of the event during 2020 and the early part of 2021 has meant that income has fallen from £3.1 million to £1.4 million. The only income realised for the 2020 London Marathon has been sponsorship received in advance and from the virtual event. We have also observed a drop in income from corporate and philanthropy by £1.2 million, community fundraising by £0.5 million and events income by £0.8 million. These income streams were impacted due to the infeasibility of being able to run face to face events and the disruption faced by our corporate supporters.

However, our continued investment in online and mainstream media has, in addition to broadening the awareness of our cause, led to sustainable growth in individual giving and regular giving. Both of these areas have seen growth during the year and provide core income streams with which we can engage with our supporters. This year the number of regular givers we have, through various channels, has grown from 42,000 to 55,000. This has been as a result of acquisition expenditure incurred in the current and previous years.

Our individual giving income stream has achieved income of £7.5 million this year, an increase of £1.5 million. This reflects the success of our appeals programme, raffles and acquisition campaigns during the year. Our legacy income has also risen during the year by £0.7 million to £2.1 million.

The uncertainty of the pandemic, and the impact on our income streams and risk profile, has meant that we have carefully considered our cost base and completed various cost saving initiatives, including restructuring of our staffing. In addition, we were able to save some costs due to the cancellation of events and the closure of the office. Due to the nature of the London Marathon, where places are bought in advance of the race, we were able to roll forward these costs to allocate against future races. We were therefore able to manage our expenditure down from £16.8 million to £15.3 million. This is despite increasing our level of grant awards from £4.2 million to £7.4 million – with £2.5 million being contributed to the co-funded

Cancer Research UK-Children with Cancer UK Innovation Awards and £1 million being awarded to Teenage Cancer Trust for Emergency Coronavirus Appeal.

31

Financial Statements For the year ended 31 December 2020

During these challenging circumstances, we ended the year with a deficit of £1.6 million that has decreased our total reserves to £9.3 million. We have been able to manage our costs down in response to the impact on our income streams and economic uncertainty. Despite the decrease in our reserve position, they are still at a level that gives us stability during these uncertain times.

For every £1 donated, we spend 84p on fighting childhood cancer.

We reinvest 14p from every £1 raised, to raise even more money.

For every £1 we spend on fundraising, we raise £7 more.

Reserves

At the end of the year, the charity held £9,295,761 (2019: £10,901,419) in total reserves. All funds were held in unrestricted reserves with none in in restricted reserves (2019: £527,344).

The restricted funds comprise of donations that were to be spent on specific causes and projects as detailed in Note 19.

Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity’s charitable purposes.

The Trustees are aware of their role as custodians of these funds and plan to disburse the funds in a structured and cautious manner to meet the long term objectives of the charity

The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year’s grant award programme. The remainder, is set aside for fluctuations in income that could impact the charity’s ability to carry out its services.

Therefore, £4M has been set aside from total reserves to fund the current year’s grant award programme of £4M, leaving approximately £5.3M as a reserve for operational expenditure. Heading in to 2021 with reduced activity and operational expenditure planned due to COVID-19, this buffer is a reduction from the previous financial year. £5.3M will enable the charity to operate without any income for approximately 8 months. This has exceeded the target of 6 months, but due to continued COVID-19 uncertainty, this was felt by the Trustees to be a prudent approach.

As a result of the changing environment due to COVID-19 the reserves were reviewed towards the end of 2021. The Trustees aim to review the policy again in 2022 after the full impact of COVID-19 becomes clearer and to ensure that the charity can continue to meet both its short and long term obligations.

32

Financial Statements For the year ended 31 December 2020

STRATEGIC PLANS 2020 AND BEYOND

In 2019, we reviewed our fundraising strategy and revisited our strategic vision and mission(s) to ensure they remained true to our charitable aims and objectives.

Our vision is: A world where every child survives cancer.

To achieve this vision, we will continue with our primary mission which is to fund scientific research to:

  1. better understand the causes of childhood cancer.

  2. find kinder and safer treatments and ultimately to find cures for all forms of childhood cancer.

Alongside this funding we also look to support initiatives which help promote earlier diagnosis from healthcare professionals so that childhood cancer can be caught earlier, which in turn will support better outcomes for the child.

Our secondary mission is to support children and their families during and after their cancer treatment by supporting welfare projects often provided by other specialist charities. Examples include the grant to Teenage Cancer Trust for the provision of frontline services during the COVID-19 pandemic, the Beads of Courage UK oncology programme and grant to the Little Brains Trust.

Collaboration

COVID-19 has laid bare the challenges that charities are facing on a daily basis. For progress to be made in the area of childhood and young adult cancers, charities, Governments and researchers need to come together to improve survival rates and outcomes for patients and families.

We need to work together with other cancer charities in order to resolve the difficult challenges that we are facing and seek collaborations to fulfil our mission. We were founding members of the Children and Young People with Cancer Coalition and continue to play an active part. We are keen to continue developing this collaboration of cancer charities, across the UK, to ensure that we are all working efficiently and effectively towards the same aim.

We have a strong track record of providing funding to other charities which understand the support needed by children and young people who are going through cancer treatment. We have historically funded charities that provide this support on the front line including CLIC Sargent, Ronald McDonald Charities and Teenage Cancer Trust.

33

Financial Statements For the year ended 31 December 2020

Looking ahead we have embarked on an important new collaboration with Cancer Research UK as we have co-funded five new, innovative research projects to transform our understanding of children’s and young people’s cancers and find new ways to prevent and treat these complex cancers. Joining forces allows us to invest more in this field and to engage and unite a broader network of childhood cancer expertise.

Governance

As a long established charity, we are always keen to make improvements and ensure we are following best practice. In January 2021 the Board of Trustees instructed an external review of our Governance. Two new Trustees joined the board in 2021 and we expect there to be continued changes to the Board of Trustees over the next couple of years. The Trustees want to ensure that there are the correct processes in place around governance and oversight of the organisation to operate effectively as we enter into a period of transition.

Due to investments made in 2019 we were able to implement our new grant database, which is now helping us to administrate and manage all our financial grants better. Crucially, it will help us track the impact of our grants in future years. The investment will continue with the creation and implementation of our Scientific Strategy, which has had its launch delayed until 2022. This strategy will create a clear path to demonstrate how we will support research in the future for all our supporters and fundraisers.

We have undertaken a comprehensive review of our Welfare program. This important area of our spending has always focused on delivering the best outcome/support for families that are affected by childhood cancer. We have recently implemented new Terms and Conditions for all Welfare grant applications and grants to ensure that we are able to administer support where it is most needed that will deliver the greatest impact for young cancer patients and their families.

Consolidation

Due to the COVID-19 pandemic, 2020 was a very difficult time for the charity as it resulted in an annual reduction in income of 30%. Unfortunately, with plans for growth of the charity in early 2020 further staff were employed, but it was apparent towards the end of the year that the situation across the country and for the economy was unlikely to change in the immediate future. It was identified by the Trustees that the ongoing staff costs would be unsustainable based on our new income. In December 2020 we took the very difficult decision to undertake a

consolidation of expenditure, which included utilisation of the furlough scheme and a redundancy process. We would like to thank all members of the team who were affected for their professionalism and the dedication demonstrated throughout this difficult time.

34

Financial Statements For the year ended 31 December 2020

People

The priority for 2021 and onwards will be to focus on building the morale of our existing staff, ensure that all training needs are met and to create a highly motivated team. We are committed to remaining an excellent place of work that values and prioritises staff wellbeing. A number of staff initiatives including introducing a Wellness Hub, weekly virtual catch ups and wellness hours have been implemented for 2021. Additional initiatives along with an assessment of our working practices are part of our ongoing plans. COVID-19 has altered our approach to working in many ways and we will work with staff to ensure that we support them to work to the best of their ability.

Attracting new supporters

To ensure the long term financial security of the charity we intend to continue our efforts to attract new supporters. Since 2018, when we embarked upon a large rebranding project and invested into a new TV advert we have attracted a new demographic of supporter, typically younger families. We will continue our work to attract new supporters, primarily with a renewed focus on digital platforms such as Facebook, Instagram and other social media platforms alongside investment into our website. This strategy has become ever more important since the COVID-19 pandemic as we search for more ways to ensure financial stability whilst in-person fundraising will inevitably continue to take a back seat. We also recognise there are unexplored opportunities in corporate, philanthropic and trust fundraising, so we will invest resource into these areas over the coming years.

Fundraising

The ongoing impact COVID-19 has had on our income, has resulted in a 30% decrease in our income from 2019 to the 2020 financial year. We need to ensure that now, more than ever, we continue to work hard to maximise the impact of existing and new fundraising opportunities across the sector.

Individual Giving includes a range of multi-channel appeals and ways to support our vital work including playing our Grand Draw or Weekly Lottery, donating a one-off gift, signing up for a regular gift or leaving a gift in your Will. It continues to be our core area of our fundraising with over 69% of our 2020 income coming from this area. The pandemic presented a new opportunity to bring on board new ‘locked down’ audience through our TV adverts, as well as more time to engage and seek support from our existing supporters. Our focus on both regular giving and gaming (Grand Draw and Weekly Lottery) contributed to our 10% increase in income from 2019 to 2020. For 2021 and 2022, we will continue to look at ways to continue to grow our acquisition channels and revisit activity that was postponed with the pandemic. Our priority remains to take a supporter-centric approach and look at opportunities to build long-term relationships with our charity that could lead to gifts in Wills; another vital and growing source of income for our charity. Ensuring we offer a wide range of easy ways to support our work and taking a test-and-learn approach to our programme will remain a priority.

35

Financial Statements For the year ended 31 December 2020

Sports events has always been a key area of fundraising, with the Virgin Money London Marathon raising over £3m in 2018 and 2019. Due to COVID-19, we saw the majority of our sports events cancelled or postponed in 2020. The result of this was an income decrease of 62% from sports events compared with the 2019 financial year. Looking forward we plan to get to pre pandemic income from sports events (£4.549m) by the end of the 2023 financial year. We will do this by focusing on our supporter experience, reviewing and diversifying our sports events offering, and ensuring that we remain flexible and agile to the changing sports events sector.

COVID-19 saw the cancelation of our event portfolio and a decrease in the number of community fundraising activities, which resulted in a 52% decrease of income from Community and Events fundraising in 2020 compared with the 2019 financial year. We plan to get to pre pandemic income from Community and Events (£2.641m) by the end of the 2023 financial year. To achieve this we will focus on delivering excellent supporter experience, review and develop our portfolio of events and campaigns, revive The Children with Cancer UK Ball from 2022, develop boards of highly motivated and well networked supporters, engage more patient families to support the cause, and make sure we are proactive and adapt to the changing fundraising environment.

A key growth and relatively untapped area of fundraising that we plan to explore includes corporate, philanthropy and trusts. We want to create a robust income stream for the charity with a healthy future pipeline. To do this we have actively recruited Trustees with knowledge, contacts and expertise to help lead these fundraising areas. We will aim to raise £2.5m by 2023 by actively pursuing £25k plus partnerships, multi-year partnerships, creating cultivation plans, and exploring and utilising all networks across the organisation.

We will ensure our fundraising is as cost efficient as possible ensuring we produce the net income which will allow us to fulfil our charitable objectives. Operational efficiency will also be key and we will continue to utilise systems and tools which allow us to spend much more time with our donors than on internal administration and processing.

We continue to demonstrate our ability to operate remotely with all staff fully functioning from home, allowing us to rethink our space requirements in the future with undoubted operational savings.

Marketing and Communications

The COVID-19 pandemic has taught us to be adaptable and to approach our communications strategy with flexibility. It has certainly made it harder to raise awareness on some platforms because we have been fighting for space amongst all of the COVID-19 content, for example in the media. However, this year has also presented us with new opportunities to exploit and we have managed to achieve a great deal in 2020 against all odds.

36

Financial Statements For the year ended 31 December 2020

There was a very quick shift in focus toward our digital communications and fundraising programmes. Digital communications were the only way for much of 2020 to reach new audiences and connect with our existing supporters. We focused on providing quality and compelling content for our social media channels and on our website to really engage people with the issues of childhood cancer. We found that more people were watching and commenting on our videos and stories, particularly on social media. We also shifted our resource into ensuring our website was as optimised as possible for accepting donations to ensure that it was a wellfunctioning income stream for the charity.

As the year progressed, and the projected cut in income was being fully understood, we also needed to consolidate our expenditure. This has resulted in number of roles not being replaced within the marketing and communications team. This means that our output will reduce by around half for 2021 and how we will adapt will be reflected in our strategy moving forwards.

For 2021 the strategy remains the same that we are focusing on raising awareness of cancer in children and young people and supporting our fundraising teams to generate income for the charity. We will be doing this in a couple of key areas – through engaging with the media and through digital communications channels.

It is important to increase awareness of Children with Cancer UK by raising our profile within the media and securing coverage of our work. We will continue to develop the in-house press office function and our reputation by providing an exceptional service to the media. We will also work to respond to issue affecting children and families with caner in the media by reacting through key spokespeople to further our brand presence.

Our focus on digital continues including undertaking some research to understand our existing audiences better and how they interact with us. We aim to put our supporters at the heart of how we communicate.

The COVID-19 pandemic has meant that there is increased need for digital to deliver fundraising and marketing goals, which means we will continue to test out different optimization tests to ensure we are gaining as many donations as possible. We continue to increase our investments into digital marketing in 2021 compared to the previous year.

Operations

Our staff have been working from home now for over a year, which has meant we have adapted our processes and systems to ensure that this can continue efficiently and effectively. We will work with staff to assess our working practices longer term. It will also include a review of our systems, which was delayed from 2020 due to the added pressures of COVID-19 on the charity. This review will specifically look at the IT systems along with the Fundraising and Finance databases to ensure they complement the fundraising and communications strategy. This review will ensure the charity maximises its fundraising potential and is able to adapt effectively to the changing operational landscape.

37

Financial Statements For the year ended 31 December 2020

Going Concern

The accounts are approved during a period where there is continued uncertainty as a result of COVID-19. The Charity is constantly assessing the short and long term impact on its fundraising activities in the current climate.

The charity has presented multiple budgets for the current year which takes into account the uncertainty of plans to return to business as usual. These budgets consider various best and worst case scenarios with many outcomes. By closely monitoring the likelihood of each scenario in real time the Trustees are able respond promptly and effectively.

In their assessment of going concern the Trustees have considered the current and ongoing impact on the charity as a result of the COVID-19 virus. This continues to have a significant impact on certain activities in the current financial year including the Ball, running events and community based fundraising, which made up approximately 40% of the charity’s income prior to COVID-19. With the return of certain events like the London Marathon in October 2021, the Trustees are optimistic that the return to pre COVID-19 fundraising levels will be possible. The Ball for 2021 was cancelled with an anticipated return date in 2022. At the time of writing indications are that it is possible to have a return to pre COVID-19 by the end of 2022. The success of the recent London Marathon event in October 2021 is an encouraging sign. The Trustees are aware that if the situation worsens and becomes prolonged then this view may change.

The Trustees have considered scenarios including a worsening of the current recovery with events being cancelled and virtual events being prevalent. There are currently significant cash balances should additional liquidity be required through this period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

The ultimate impact of COVID-19 on the charity is yet to be seen. Our cash deposits could easily be drawn down should working capital be required. Appropriate consideration of risks as part of its normal risk management processes and mitigating actions both already taken and available to be taken.

The trustees believe that although there is uncertainty regarding COVID-19 the charity remains in a strong position to use its cash deposits to take advantage of any opportunities and they are at a sufficient level to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly the Trustees consider it appropriate for the going concern basis to be adopted for these accounts.

38

Financial Statements For the year ended 31 December 2020

Investments

The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.

The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore, the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.

The charity investment policy is reviewed regularly and states that the longer term funds must produce the best financial return for an acceptable risk. The fund must balance the need to support research grants with the objective for capital growth and inflation protection. The Trustees feel the 2020 performance of the investments met the objectives of the policy and recognise the opportunity to identify higher performing funds for 2021 whilst still within an acceptable risk.

The charity currently holds £10.1M of investments held for the longer term. This comprises £1.8M in an investment portfolio managed by Barclays Investment Managers and £8.3 in cash deposits. The charity also holds £4.6M in short term cash deposits.

The Trustees are keen to ensure that the cash funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2020, our grant liabilities are close to £10.3M (2019: £10.6M).

Risk and internal control

The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

As part of the Charity’s risk management process the Trustees acknowledge their responsibility for the Charity’s system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity’s objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

39

Financial Statements For the year ended 31 December 2020

Principal risks and uncertainties

At the start of 2020 the COVID-19 Pandemic was not an identified risk. Plans were immediately put in place and a full review of all the strategic risks that had previously been identified during the year in review was undertaken to incorporate this new risk. There was a high level of Trustee engagement throughout this period. The Chair of Trustees was in regular contact with the CEO during this time with updates to the Board. Frequent discussions of key issues amongst the Board also occurred during this time. One Trustee regularly attended the weekly update meetings attended by all staff. Each team has been assigned a Trustee that they can engage with to assist Trustee oversight.

Along with the review of the strategic risks that had a particular focus on COVID-19, a separate COVID-19 risk log was developed. This has been regularly updated to respond to the changing environment.

The pandemic has had an impact on multiple areas of the organisation. Whilst the long term impact of the pandemic is still to be seen, several plans have been implemented to mitigate this risk in the short term with longer term plans being developed. These short term strategies continue and include regular management meetings, continuous review of up to date income figures, engagement with all suppliers to review costs, evaluation and renegotiation of contracts where appropriate, redeployment of resources where necessary and identification, exploitation and investment of any new fundraising opportunities like digital fundraising.

The Charity continues to be heavily reliant on mainstream fundraising income to fund charitable activity, the major risk being faced is that income falls to a level that compromises the Charity’s ability to meaningfully fund future charitable activity – whilst at the same time maintaining reserves at a stable level. This risk continues to be managed by the Charity by diversifying its income streams and investing in new fundraising channels. The Charity is continuing the process of implementing ‘strategic imperatives’ that will guide its future vision and strategy.

The seven strategic risks that were identified prior to COVID-19 are listed below.

oFundraising oProfile & Brand
oRegulatory compliance oFinancial
oInfrastructure & Operations oGovernance
oCharitable Impact

These risks have been reviewed with a new focus of COVID-19 and assessed in terms of probability and impact with a mitigation strategy put in place if required. This forms part of the charity’s annual risk management strategy.

The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our trading income streams to manage this risk.

40

Financial Statements For the year ended 31 December 2020

The strategic risks have been reviewed by the Trustees. Some of the issues discussed include, Governance Review, Strategy Income position, succession planning and organisational structure. These discussion points intersect with all the strategic risks and will continue to be reviewed regularly by both the Trustees and Senior Management.

Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).

The Trustees have considered and acknowledge the principles and recommendations set out in the Charity Governance Code. The Senior Leadership Team were tasked of reviewing the Charity's governance against the Charity Governance Code and identifying key areas for development. It was recommended to the Trustees that an independent Governance Review was initiated. The Trustees instigated this review and tasked the Senior Leadership Team to implement all recommendations. Significant progress has been made with nearly 50% of the recommendations completed and plans in place for the remaining items to be addressed within the next 12 months.

Governing documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11[th] November 2003 as amended by special or written resolutions, dated 30[th] November 2004, 22[nd] December 2006, 12[th] May 2007 and 28[th] July 2016. On 14[th] May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11[th] May 2011.

The charity operates under its Trust Deed (dated 4[th] January 1988) and Variation of Trust Deed (dated 10[th] December 2003).

41

Financial Statements For the year ended 31 December 2020

Aims and Objectives

Purposes and Aims

The charity’s objects as amended by written resolution of 12[th] May 2007, and 28th July 2016 are shown below:

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities.

We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 22.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of seven members (2019: six). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

42

Financial Statements For the year ended 31 December 2020

Trustee appointment and induction

There were three new appointments (2019: two) to the Trustee Board in 2020 and an additional two post year end. One Trustee left the board on 22[nd] September 2020. The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication ‘The Essential Trustee: What you need to know’ as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

Salary Bands and grading of job roles was introduced in 2018. Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands will be revised as required and at least once every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

43

Financial Statements For the year ended 31 December 2020

Trading Subsidiary

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship and commercial agreements.

The trading activities generated profit for the year of £11,638 (2019: £18,625) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.

The trading subsidiary holds assets of £45,069 (2019: £44,706) and liabilities of £44,969 (2019: £44,606) with funds of £100 as at 31st December 2020.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a related party and conflict of interest policy in place which accompanies the declaration of interests submissions completed by all Trustees and senior management. An internal conflict of interest register is in place which is updated when a conflict of interest has been identified and is reviewed at least annually.

44

Financial Statements For the year ended 31 December 2020

Grant making policy

It is the Trustees’ policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2020, a total of £1,285,296 (2019: £918,000) was awarded to welfare projects.

Research grants

The Trustees aim to award an increasing proportion of the charity’s grants to scientific and medical research in child and young person cancer. The charity’s Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our scientific advisor panels (SAPs) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.

In 2020, a total of £6,167,773 (2019: £3,353,277) was awarded to research projects. This figure includes £2.5m awarded as part of the equally co-funded Cancer Research UK–Children with Cancer UK Innovation Awards. Project funding is directed in two areas of concern:

  1. Research into treatment and survival 2. Research into prevention and causes

We also fund some 5-year Post-doctoral Fellowships and Clinical PhD Studentships on these topics at leading research Institutions regarding child and young adult cancer.

45

Financial Statements For the year ended 31 December 2020

REFERENCE AND ADMINISTRATION

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:

Eddie O’Gorman OBE (Founder and Chair of Trustees) Sandra Mileham Linda Robson Virna Midgley Caroline Randerson (Appointed 8[th] September 2020) Ann Amaya-Torres (Appointed 8[th] September 2020) Alasdair Philips (Left Board 22[nd] September 2020) Nick Goulden (Appointed 12[th] December 2020) David Gibbs (Appointed 22[nd] February 2021) Alex Leitch (Appointed 12[th] May 2021)

Chief Executive Officer

Cliff O’Gorman (Appointed 6[th] October 2020)

Senior Management

Gary Murphy (Head of Finance) Hannah Chambers (Head of Marketing and Communications) Emily Roff (Head of Events, Community and Sports) Camelia Vasilcan (Head of Database) Fiona Judge (Head of Supporter Care) Fadil Dugolli (Head of IT)

Previous members of the Senior Management during the year were

Mark Brider Sophie Wiles Zahra Scott-Gunnlaugsson Caroline Lane Samia Choudhri

46

Financial Statements For the year ended 31 December 2020

Registered Charity Number Registered Company Number 298405 4960054

Principal office

51 Great Ormond Street, London WC1N 3JQ

Solicitors

Bates Wells, 10 Queen Street Place, London, EC4R 1BEB

Auditors

Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW.

Bankers

National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ

Contact details

Children with Cancer UK 51 Great Ormond Street, London WC1N 3JQ Tel: 020 7404 0808 Email: info@childrenwithcancer.org.uk www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our two Scientific Advisory Panels (SAP) who freely give their time and expertise to help drive forward our fight against childhood cancer. Research into childhood cancer is a broad field and we aim to reflect the diversity of the field amongst the membership of our Treatment and Survivorship and our Causes and Prevention Panels. Some members may sit on both panels.

The Chair of the Treatment SAP is Dr Owen Williams, PhD, Reader in Cancer Biology and Head of Cancer Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust

The Chair of our Causes and Prevention SAP is Professor Geoff Pilkington, PhD CBiol FRSB FRCPath, Professor of Cellular and Molecular Neuro-Oncology and Head of Brain Tumour Research Centre, University of Portsmouth.

47

Financial Statements For the year ended 31 December 2020

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees’ Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company’s transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity’s constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company’s auditor in connection with preparing the audit report) of which the charitable company’s auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company’s auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 10[th] October 2021 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:

Eddie O’Gorman OBE Founder and Chair of Trustees

Date: 22[nd] November 2021

48

Financial Statements For the year ended 31 December 2020

Independent Auditor’s Report to the Trustees of Children with Cancer UK

Opinion

We have audited the financial statements of Children with Cancer UK (‘the charitable company’) [and its subsidiary (‘the group’)] for the year ended 31 December 2020 which comprise the Group Statement of Financial Activities, the Group and Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's or the group’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

49

Financial Statements For the year ended 31 December 2020

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the course of our audit

Matters on which we are required to report by exception

In light of the knowledge and understanding of the group and charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report included within the trustees’ report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees’ responsibilities statement set out on page 47, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

50

Financial Statements For the year ended 31 December 2020

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team. We then designed and performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion.

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006, taxation legislation, together with the Charities SORP (FRS 102). We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company’s and the group’s ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context were Data Protection Regulation (GDPR) and employment legislation.

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any.

We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the timing of recognition of income and the override of controls by management. Our audit procedures to respond to these risks included enquiries of management and the Board of Trustees about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory correspondence with the Charity Commission, and reading minutes of meetings of those charged with governance.

51

Financial Statements For the year ended 31 December 2020

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

Andrew Thomas

Senior Statutory Auditor For and on behalf of Crowe U.K. LLP Statutory Auditor London

Date:

52

Financial Statements For the year ended 31 December 2020

Consolidated statement of financial activities for the year ended 31 December 2020 (Incorporating an income and expenditure account)

Note Total
restricted
funds		 Total
unrestricted
funds		 Total
2020		 Total
2019
£ £ £ £
Income from:
Donations and legacies 4 274,867 13,308,831 13,583,698 16,378,190
Other tradingactivities 4 - 48,994 48,994 828,225
Income from
investments		 - 129,182 129,182 82,636
Other income - 131 131 41,375
Total Income 19 274,867 **13,487,138 ** 13,762,005 17,330,426
Expenditure on:
Raisingfunds 6 - 2,057,943 2,057,943 3,956,547
Charitable activities 6, 8 754,531 12,529,698 13,284,229 12,860,400
Total Expenditure 6,16 **754,531 ** 14,587,641 15,342,172 16,816,947
Net change in
investments		 12 - (25,491) (25,491) 216,320
Net
(expenditure)/income		 (479,664) (1,125,994) (1,605,658) 729,798
Transfers between
funds		 19 (47,681) 47,681 - -
Net movement in
funds		 (527,344) (1,078,313) (1,605,658) 729,797
Reconciliation of funds:
Total funds brought
forward		 527,344 10,374,075 10,901,419 10,171,622
Total funds carried
forward		 19 - 9,295,762 9,295,761 10,901,419

The comparative figures for each fund are shown in note 3 to the financial statements.

53

Financial Statements For the year ended 31 December 2020

Balance sheet as at 31 December 2020

Company Number: 4960054

ompanyNumber: 4960054
2020 2019
Note Group Charity Group Charity
Fixed assets £ £ £ £
Investments 12 10,133,555 10,133,655 11,157,521 11,157,621
10,133,555 10,133,655 11,157,521 11,157,621
Current assets
Debtors andprepayments 14 3,110,245 3,149,113 4,272,145 4,299,474
Cash deposits 4,554,746 4,554,746 4,445,032 4,445,032
Cash at bank and in hand 2,069,985 2,027,417 2,246,853 2,215,824
9,734,976 9,731,276 10,964,030 10,960,330
Creditors: amounts falling
**due withinone year **
Grants 15,16 (1,982,298) (1,982,298) (3,850,858) (3,850,858)
Other 16 (670,401) (666,801) (692,634) (689,034)
Net current assets 18 7,082,277 7,082,177 6,420,538 6,420,438
Total assets less current
liabilities		 **17,215,831 ** **17,215,831 ** 17,578,059 17,578,059
Creditors: amounts falling
due after more than oneyear
Grants 15 (7,920,071) (7,920,071) (6,676,640) (6,676,640)
Net assets 9,295,760 9,295,760 10,901,419 10,901,419
Represented by:
Unrestricted funds **9,295,761 ** **9,295,761 ** **10,374,075 ** 10,374,075
Restricted funds - - 527,344 527,344
18,19 9,295,761 9,295,761 10,901,419 10,901,419

The net deficit for the financial year dealt within the financial statements of the parent charitable company was £1,605,658 (2019: net surplus £767,274).

The notes on pages 54 to 72 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 22[nd] November 2021.

Eddie O’Gorman OBE Trustee

Sandra Mileham Trustee

54

Financial Statements For the year ended 31 December 2020

Consolidated cash flow statement for the year ended 31 December 2020

2020 2019
£ £
Cash flows from operating activities:
Net cashprovided byoperatingactivities a) (1,190,010) (1,316,750)
Cash flows from investing activities:
Dividends and interest from investments 129,182 82,636
Net additions/(disposals)in theyear (4,939) (1.678)
Net cashprovided byinvesting activities 124,243 80,958
Change in cash and cash equivalents in
the reporting period		 (1,065,767) (1,235,792)
Cash and cash equivalents at the
beginning of the reporting period		 b) 16,045,739 17,281,531
Cash and cash equivalents at the end of
the reporting period		 b) 14,979,972 16,045,738
Notes to the Cash flow Statement
a) Reconciliation of net (expenditure) to
net cash flow from operating activities		 2020
£		 2019
£
Net (expenditure)/income for the reporting
period		 (1,605,658) 729,797
Adjustmentsfor:
Dividends, interest and rents from
investments		 (129,321) (82,636)
InvestmentManager Fees 4,939 5,141
Net Changein investments 25,491 (216,320)
Decrease / (increase)indebtors 1,161,900 (836,206)
(Decrease) /increaseincreditors (647,361) (916,526)
Net cash provided by (used in) operating
activities		 (1,190,010) (1,316,750)
b) Analysis of cash and cash equivalents 1 January
2020		 Cashflow 31 December
2020
£ £ £
Cashat bankandin hand 2,246,853 (176,868) 2,069,985
Cash held as short term investments 4,445,032 109,714 4,554,746
Cash held aslong term investments 9,353,853 (998,612) 8,355,241
16,045,738 (1,065,766) 14,979,972

55

Financial Statements For the year ended 31 December 2020

Notes to the financial statements for the year ended 31 December 2020

1. Charity information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 51 Great Ormond Street, London WC1N 3JQ. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.

2. Accounting policies

(a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as ‘the Group’. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity’s financial instruments.

In their assessment of going concern the Trustees have considered the current and developing impact on the charity as a result of the COVID19 virus. This has had a significant impact on certain activities in the current financial year including running events, community based fundraising. The Ball for 2020 was cancelled with an anticipated return date in 2022.These events made up approximately 40% of the charity’s income prior to COVID-19.

With the return of certain events like the London Marathon in October 2021, the Trustees are optimistic that the return to pre COVID-19 fundraising levels will be possible. The Trustees are aware that if the situation worsens and becomes prolonged then this may change.

56

Financial Statements For the year ended 31 December 2020

The charity has presented multiple budgets for the current year which takes into account the uncertainty and consider various best and worst case scenarios with many outcomes. By closely monitoring the likelihood of each scenario in real time the Trustees are able respond promptly and effectively.

There are currently significant cash balances should additional liquidity be required through this period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

Accordingly, the Trustees believe the Charity's financial resources are sufficient to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements and have therefore prepared the financial statements on the going concern basis.

(c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group’s trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group’s short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

In the application of the charity’s accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

57

Financial Statements For the year ended 31 December 2020

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

(e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

(f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

(g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor’s intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

58

Financial Statements For the year ended 31 December 2020

Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be received. The grant in connection to the job retention scheme has been recognised in the period to which the underlying furloughed staff costs relate to.

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2020, the charity made a contribution of 9% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

59

Financial Statements For the year ended 31 December 2020

(k) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

(l) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

(m)Private Medical Insurance

Since October 2017, permanent employees are entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2020, the charity paid a premium based on the employee’s ages per month to all employees after serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.

60

Financial Statements For the year ended 31 December 2020

3. Consolidated statement of financial activities for the year ended 31 December 2019

Total
restricted
funds
£		 Total
unrestricted
funds
£		 Total
2019
£
Income from:
Donations and legacies 240,594 16,137,595 16,378,190
~~Other trading activities~~ ~~-~~ ~~828,225~~ ~~828,225~~
Income from investments - 82,636 82,636
Other income ~~-~~ ~~41,375~~ 41,375
Total Income 240,594 17,089,831 17,330,426
Expenditure on:
Raisingfunds - 3,956,547 3,956,547
Charitable activities 621,947 12,238,453 12,860,400
Total Expenditure 621,947 16,195,000 16,816,947
Net change in investments - 216,320 216,320
Net (expenditure)/income (381,353) **1,111,151 ** 729,798
Transfers between funds (155,781) **155,781 ** -
Net movement in funds ~~(537,134)~~ ~~1,266,931~~ ~~729,797~~
~~Reconciliation of funds:~~
Total funds brought forward 1,064,478 9,107,144 10,171,622
Total funds carried forward 527,344 10,374,075 10,901,419

4. Income

e
2020
£		 2019
£
Donations and legacies
Appeals and associated donations 4,924,928 4,357,740
~~Committedgiving~~ ~~2,632,190~~ ~~2,080,202~~
~~Community fundraising~~ ~~1,321,743~~ ~~1,813,260~~
~~Corporate and trust donations~~ ~~891,830~~ ~~2,163,789~~
Legacies(see contingent asset below) 2,074,903 1,396,017
Sports events 1,738,104 4,549,199
Transfer of funds(See below) - (7,177)
13,583,698 16,353,030
~~Scratch cards(see scratch card income below)~~ ~~-~~ ~~25,160~~
~~————~~ ~~————~~
13,583,698 16,378,190
———— ————
Other trading activities
Events 48,994 828,225
~~————~~ ~~————~~
48,994 828,225
~~————~~ ~~————~~

Included in Donations and legacies in 2020 is a government grant in the form of the Job Retention Scheme for £29,750. Included in 2019 is a (£7,177) adjustment for £1,064,748 of funds received in 2018 which relates to the transfer of funds from Children’s Leukaemia Trust (charity number 1000341). This is the difference of expected and actual funds received. See Note 19.

61

Financial Statements For the year ended 31 December 2020

Contingent asset – legacy income

As at 31 December 2020, the charity had been notified of a further 12 residuary and 16 pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £253,187 which has not been accrued.

5. Lottery income

As part of the charity’s Gambling Commission License (Non Remote License - 000-004700-N306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2020:

Ticket sales
£
WeeklyLottery
 530,804
Christmas Raffle(draw 17
~~th~~January2020)
 501,539
~~Spring Raffle(draw 5~~
~~th June 2020)~~
 ~~419,309~~
~~Summer Raffle(draw 18~~
~~th September 2020)~~		 ~~465,085~~
Total 1,916,737

As the Christmas raffle spans two accounting periods, £832 was received during 2020 and £500,707 during 2019. All other ticket sales were received during 2020 only. All ticket sales have been included within the total income for 2020 and 2019.

In line with the requirements under Social responsibility code provision 4.3.1 of the License Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2020.


otteries promoted in 2020.
Lottery type Lottery Name Percentage proceeds
returned to Charity %
Managed directlybyChildren With Cancer UK WeeklyLottery 59%
Managed directlybyChildren With Cancer UK Children with Cancer Grand Draw 69%
**Total ** 67%

62

Financial Statements For the year ended 31 December 2020

6. Total expenditure

Staff Costs
£		 Direct Costs
£		 Support and
Governance
£		 2020 Total
£		 2019 Total
£
Expenditure on Raising
funds
FundraisingCosts 718,582 1,006,665 332,696 2,057,943 3,956,547
Expenditure on Charitable
activities
Research into Prevention &
Causes		 310,332 2,329,940 111,294 2,751,565 4,105,839
Research into Treatment 323,541 4,843,792 109,506 5,276,839 1,985,897
~~Welfare~~ ~~394,214~~ ~~2,162,572~~ ~~156,122~~ 2,712,907 2,605,761
~~Raising Awareness~~ ~~803,778~~ ~~1,421,488~~ ~~317,650~~ 2,542,917 4,162,903
————— ————— ————— ————— —————
1,831,865 10,757,792 694,571 13,284,229 12,860,400
————— ————— ————— ————— —————
2,550,447 11,764,457 1,027,267 15,342,172 16,816,947
========= ========= ========= ========= =========
Staff Costs
£		 Direct Costs
£		 Support and
Governance
£		 2019 Total
£
Expenditure on Raising
funds
~~Fundraising Costs~~ ~~772,912~~ ~~2,656,151~~ ~~527,484~~ 3,956,547
Expenditure on Charitable
activities
~~Research into Prevention &~~
Causes		 271,175 3,666,016 168,648 4,105,839
Research into Treatment 292,385 1,527,405 166,107 **1,985,897 **
Welfare 346,718 2,010,255 248,788 **2,605,761 **
RaisingAwareness 841,904 2,833,049 487,950 4,162,903
~~—————~~ ~~—————~~ ~~—————~~ ~~—————~~
~~1,752,182~~ ~~10,036,725~~ ~~1,071,493~~ 12,860,400
————— ————— ————— —————
**2,525,094 ** 12,692,876 1,598,977 16,816,947
========= ========= ========= =========

63

Financial Statements For the year ended 31 December 2020

7. Support costs

Support costs are split as follows:

Office
Administration
£		 Operational
Management
£		 Finance /
IT / HR
£		 Communications
and Marketing
£		 Governance
£		 2020 Total
£
Expenditure on
Raising funds
FundraisingCosts 45,952 89,976 119,230 57,693 19,845 332,696
Expenditure on
Charitable
activities
~~Research into~~
Prevention &
Causes		 17,139 20,766 44,470 21,518 7,401 111,294
Research into
Treatment		 16,864 20,432 43,755 21,172 7,283 109,506
Welfare 24,042 29,130 62,382 30,185 10,383 156,122
~~Raising Awareness~~ ~~48,917~~ ~~59,268~~ ~~126,924~~ ~~61,416~~ ~~21,125~~ 317,650
————— ————— ———— ————— ————— ————
106,963 129,595 277,530 134,291 46,192 694,571
————— ————— ———— ————— ————— ————
152,915 219,571 396,760 **191,964 ** **66,037 ** **1,027,267 **
========= ========= ======== ========= ========= ========
Office
Administration
£		 Operational
Management
£		 Finance /
IT / HR
£		 Communications
and Marketing
£		 Governance
£		 2019 Total
£
Expenditure on
Raising funds
FundraisingCosts 56,035 146,794 179,023 77,519 68,113 **527,484 **
Expenditure on
Charitable
activities
~~Research into~~
Prevention &
Causes		 19,162 38,468 61,218 26,508 23,292 168,648
~~Research into~~
Treatment		 18,873 37,889 60,295 26,109 22,941 166,107
Welfare 28,267 56,748 90,307 39,105 34,360 **248,787 **
RaisingAwareness 55,440 111,300 177,123 76,697 67,390 487,950
~~—————~~ ~~—————~~ ~~————~~ ~~—————~~ ~~—————~~ ~~————~~
~~121,742~~ ~~244,405~~ ~~388,943~~ ~~168,419~~ ~~147,983~~ 1,071,492
~~—————~~ ~~—————~~ ~~————~~ ~~—————~~ ~~—————~~ ~~————~~
177,777 391,199 567,966 245,938 216,096 1,598.976
========= ========= ======== ========= ========= ========

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.

64

Financial Statements For the year ended 31 December 2020

8. Costs of charitable activities

Activities
undertaken
directly
£		 Grant
funding of
activities
£		 Support and
governance
costs
£		 2020 Total
£		 2019 Total
£
Research into Prevention & Causes 1,076,057 1,564,215 111,294 2,751,565 4,105,839
~~Research into Treatment~~ ~~1,036,834~~ ~~4,130,499~~ ~~109,506~~ ~~5,276,839~~ 1,985,897
Welfare 1,271,490 1,285,296 156,122 2,712,907 2,605,761
~~Raising Awareness~~ ~~2,218,516~~ ~~6,751~~ ~~317,650~~ ~~2,542,917~~ 4,162,903
——— ——— ——— ——— ———
**5,,602,897 ** **6,986,761 ** 694,572 13,284,228 12,860,390
========= ========= ========= ========= =========

9. Auditor Costs

Statutory
Audit Fee
£		 2020 Total
£
Children with Cancer UK 33,300 33,300
HelpingChildren with Cancer Ltd 3,600 3,600
——— ———
36,900 36,900
~~=========~~ ~~=========~~
Statutory
Audit Fee
£		 Other
Financial
Services
£		 2019 Total
£
Children with Cancer UK 30,700 1,428 32,128
~~Helping Children with Cancer Ltd~~ ~~3,600~~ ~~-~~ 3,600
~~———~~ ~~———~~ ~~———~~
~~34,300~~ ~~1,428~~ 35,728
========= ========= =========

Other Financial Services Includes £238 of irrecoverable VAT.

10. Staff costs

10. Staff costs
2020
£		 2019
£
Salaries and wages 2,136,936 2,104,647
National Insurance 224,044 218,778
Pension 175,283 190,084
~~Private Medical Insurance~~ ~~14,185~~ ~~11,585~~
~~—————~~ ~~—————~~
2,550,448 2,525,094
======== ========

During 2020, the following employees were paid in the following salary ranges.

Salary Range 2020
£		 2019
£
~~£130,000 - £140,000~~ ~~1~~ ~~1~~
~~£70,000 - £80,000~~ ~~1~~ ~~0~~
~~£60,000 - £70,000~~ ~~3~~ ~~1~~

There have been 7 (2019: 8) positions that have formed part of the senior leadership team during 2020. The total remuneration including pension contributions for these employees amounts to £720,745 (2019: £807,307).

65

Financial Statements For the year ended 31 December 2020

During the year there were five settlement payments (2019: two), made totalling £51,488 (2019: £97,095).

The average weekly number of contracted employees during the year was as follows:

2020 2019
No. No.
Charitable Activities 7 4
~~Raising Funds~~ ~~38~~ ~~39~~
Support, Governance, Operations and Administration 10 13
————— —————
55 56
======= =======

11. Results of the parent charity

11. Results of the parent charity
2020
£		 2019
£
~~Total income~~ ~~13,783,863~~ ~~17,354,706~~
Total expenditure (15,364,030) (16,813,313)
Unrealisedgains /(Loses) (25,491) 216,320
————— —————
Net(expenditure)/ Income (1,605,658) 757,713
========= =========

12. Investments

2. Investments
2020
£		 2019
£
Listed investments(see below) 1,778,177 1,803,668
Cash deposits 8,355,241 9,353,853
~~————~~ ~~————~~
10,133,418 11,157,521
~~————~~ ~~————~~
Market value of listed investments at 1Jan 1,803,668 1,590,812
Additions to investmentportfolio 10,185 5,389
Disposals to investmentportfolio (5,246) (3,712)
~~Investment manager fees~~ ~~(4,939)~~ ~~(5,141)~~
~~Net Investmentgain/( loss)~~ ~~(25,491)~~ ~~216,320~~
~~————~~ ~~————~~
Market value of listed investments at 31 Dec 1,778,177 1,803,668
======= =======
Listed Investments comprise the following:
Cash and short maturitybonds - 5,246
~~Multi class and other investments~~ ~~1,778,177~~ ~~1,798,422~~
~~————~~ ~~————~~
Total listed investments at 31 Dec 1,778,177 1,803,668
======= =======
Total Investments are listed in:
United Kingdom 227,607 226,360
Overseas 1,550,571 1,577,308
———— ————
1,778,177 1,803,668
~~=======~~ ~~=======~~

66

Financial Statements For the year ended 31 December 2020

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.

The income and expenditure for the year ended 31 December 2020 is as follows:

2020
£		 2019
£
Income 23,916 30,742
Administrative expenses (12,278) (12,117)
———— ————
Profit beforegift aid and taxation 11,638 18,625
~~========~~ ~~========~~

The balance sheet for the subsidiary as at 31 December 2020 is as follows:

2020
£		 2019
£
Assets 45,069 44,706
Liabilities (44,969) (44,606)
———— ————
Reserves 100 100
======== ========

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

13. Trustees’ emoluments

The Trustees received no remuneration or reimbursement of expenses during the year (2019 Nil).

14. Debtors

2020
Group
£		 2020
Charity
£		 2019
Group
£		 2019
Charity
£
Amounts due from subsidiaryundertakings - 41,369 - 41,006
~~Other debtors~~ ~~1,290,708~~ ~~1,290,708~~ ~~1,513,009~~ ~~1,516,009~~
~~Accrued income~~ ~~330,469~~ ~~327,969~~ ~~986,757~~ ~~973,080~~
~~Prepayments~~ ~~1,489,068~~ ~~1,489,068~~ ~~1,772,379~~ ~~1,772,379~~
———— ———— ———— ————
3,110,245 3,149,114 4,272,145 4,299,474
======== ======== ======== ========

67

Financial Statements For the year ended 31 December 2020

15. Grants to third parties

15. Grants to third parties
2020
£		 2019
£
Outstanding liabilities at the start of theyear 10,527,498 10,880,921
Awarded duringtheyear(note 22):
Research intoprevention and causes 1,570,272 2,718,936
Research into treatment 4,597,501 634,341
Welfare 1,285,296 918,000
Raisingawareness 20,750 18,400
———— ————
7,473,819 4,289,677
~~Under-spends onpreviousgrant awards~~ ~~(487,058)~~ ~~(250,000)~~
Paid duringtheyear (7,611,890) (4,393,100)
———— ————
Outstanding liabilities at the end of the year 9,902,369 10,527,498
======== ========
Grants fallingdue within oneyear 1,982,298 3,850,858
~~Grants falling due after more than oneyear~~ ~~7,920,071~~ ~~6,676,640~~
———— ————
9,902,369 10,527,498
========= =========

16. Creditors: amounts falling due within one year

16. Creditors: amounts falling due within one year
2020
Group
£		 2020
Charity
£		 2019
Group
£		 2019
Charity
£
~~Accruals and deferred income~~ ~~613,232~~ ~~609,632~~ ~~640,720~~ ~~637,120~~
Taxes and social security 57,170 57,170 51,914 51,914
———— ———— ———— ————
670,401 666,801 692,634 689,034
Grantspayable 1,982,298 1,982,298 3,850,858 3,850,858
———— ———— ———— ————
2,652,700 2,649,099 4,543,492 4,539,892
~~========~~ ~~========~~ ~~========~~ ~~========~~

68

Financial Statements For the year ended 31 December 2020

17. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

2020
Group
£		 2020
Charity
£		 2019
Group
£		 2019
Charity
£
Balance as at 1January 2020 51,599 51,599 53,020 53,020
Amount released to income (51,599) (51,599) (53,020) (53,020)
Amount deferred inyear 52,053 52,053 51,599 51,599
———— ———— ———— ————
Balance as at 31 December 2020 52,053 52,053 51,599 51,599
======== ======== ======== ========

18. Analysis of net assets between funds

As at 31 December 2020 2020
Group
Restricted
funds
£		 2020
Group
Unrestricted
funds
£		 2020
Group
Total funds
£		 2019
Group
Total funds
£
~~Fixed assets~~ ~~-~~ ~~10,133,555~~ ~~10,133,555~~ ~~11,157,521~~
~~Net current assets~~ ~~-~~ ~~7,082,276~~ ~~7,082,177~~ ~~6,420,538~~
Creditors fallingdue after more than oneyear - (7,920,071) (7,920,071) (6,676,640)
———— ———— ———— ————
**Net assets at the end of the year ** - 9,295,760 **9,295,661 ** 10,901,419
======= ========= ========= =========
As at 31 December 2019 2019
Group
Restricted
funds
£		 2019
Group
Unrestricted
funds
£		 2019
Group
Total funds
£		 2018
Group
Total funds
£
Fixed assets - 11,157,521 11,157,521 12,881,039
Net current assets 527,344 5,893,194 6,420,538 3,221,005
Creditors fallingdue after more than oneyear - (6,676,640) (6,676,640) (5,930,422)
———— ———— ———— ————
Net assets at the end of theyear 527,344 10,374,075 10,901,419 10,171,622
~~=======~~ ~~=========~~ ~~=========~~ ~~=========~~

69

Financial Statements For the year ended 31 December 2020

19. Statement of funds

19. Statement of funds
Year ended 31 December 2020 At the start
of the year
£		 Total
Income
£		 Total
Expenditure
£		 Transfers &
Investment
gains/losses
£		 At the end
of the year
£
Restricted funds
~~BIOMarkers of Ependymomas in Children and~~
Adolescents (BIOMECA) - Integrated Biological study
within SIOP Ependymoma II trial organised by European
Ependymoma BiologyConsortium		 - 120 - (120)
Dr Steven Pollard, University of Edinburgh. Genome
editing of human neural stem cells using nuclease-
assisted gene targeting: a tool to uncover the function of
H3F3A mutations inpaediatricglioma		 - 1,000 - (1,000)
Dr Karin Straathof, UCL Institute of Child Health,
Development of GD2-specific Bi-specific T-cell Engagers
(BiTEs)for treatment of neuroblastoma		 - 5,463 - (5,463)
Professor Louis Chesler, Institute for Cancer Research-
Individualising Management of Paediatric Cancer
Treatment - IMPACT		 - 4,488 - (4,488)
Harnessing SMAD7 induced transcriptional pathways for
novel anti-leukaemia therapies		 - 17,350 - (17,350)
Dr John Bithell, University of Oxford- Preservation and
analysis of pathology records and family histories of
children with cancer		 - 1,500 - (1,500)
Functions of DOT1L and H3K79 methylation in MLL-
rearranged leukaemia		 - 3,895 - (3,895)
~~Safety enhanced CAR T cell therapy forpaediatric AML~~ ~~-~~ ~~13,365~~ ~~-~~ ~~(13,365)~~
~~John Anderson - UCL Great Ormond Street Institute of~~
Child Health - Pilot to developCRISPR library screen for
enhanced function of G-D-T cells in paediatric solid
cancers.		 - 14,500 (14,500) -
Defne Saatci - UCL Great Ormond Street Institute of Child
Health - Investigating Late Effects of Surviving Childhood
Cancer		 - 5,000 (5,000) -
Beads of Courage UK, which helps children in all 110
children’s cancer wards in the UK visualise and articulate
their cancerjourney		 - 207,687 (207,687) -
~~CLIC Sargent~~ ~~-~~ ~~500~~ ~~-~~ ~~(500)~~
~~Children’s Leukaemia Trust. Restricted for research into~~
and trainingfor Leukaemia and Lymphoma in children		 527,344 - (527,344) - -
———— ———— ———— ———— ————
Total Restricted funds 527,344 274,867 (754,531) (47,681) -
~~Unrestricted funds~~ ~~10,374,075~~ ~~13,478,138~~ ~~(14,587,641)~~ ~~22,190~~ ~~9,295,761~~
~~————~~ ~~————~~ ~~————~~ ~~————~~ ~~————~~
Total Unrestricted funds 10,374,075 13,478,138 (14,587,641) 22,190 **9,295,761 **
Total funds 10,901,419 13,762,005 (15,342,172) (25,491) **9,295,761 **
======== ======== ======== ======== ========

Note

The restricted funds comprise donations that were to be spent on specific causes and projects. Following the dissolution of Children’s Leukaemia Trust (charity number 1000341) we benefited from a one off donation of £1,064,478 in 2018, which was restricted to research into and training for Leukaemia and Lymphoma in children. £529,957 of this fund was allocated in 2019 and a further £527,344 in 2020 leaving the total fund discharged.

70

Financial Statements For the year ended 31 December 2020

Children’s Leukaemia Trust restricted donation allocation Research into
prevention and
causes
£		 Research into
treatment
£		 Total
£
Safetyenhanced CAR T cell therapyforpaediatric AML - 250,000 250,000
Energy supplements protect pancreas from side effects of
Asparaginase		 50,000 - 50,000
Exploring the role of the tumour suppressor ATRX in Leukaemia - 50,000 50,000
Functions of DOT1L and H3K79 methylation in MLL-rearranged
leukaemia		 - 26,000 26,000
CCL17 and the early diagnosis of classical Hodgkin lymphoma – a
feasibilitystudyin theprimarycare setting		 49,780 - 49,780
~~Professor Pamela Kearns. Programmegrant: UK ALL 2011~~ ~~-~~ ~~104,177~~ ~~104,177~~
~~Optimising the use of repurposed drugs to improve the treatment~~
of children with ALL		 - 213,259 213,259
CCR9 as a novel immunotherapy target in T-cell acute
lymphoblastic leukaemia(T-ALL)		 - 249,325 249,325
Identification of novel surface antigen targets for CAR T cell
strategies inpaediatric Acute Myeloid Leukaemia stem cells.		 - 64,760 64,760
Total funds 99,780 957,521 **1,057,301 **

All other restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

Year ended 31 December 2019 At the start
of the year
£		 Total
Income
£		 Total
Expenditure
£		 Transfers &
Investment
gains/losses
£		 At the end
of the year
£
Restricted funds
Discovery of biomarkers and new therapeutic targets for
chemotherapyassociated neurotoxicity		 - 3,000 - (3,000) -
~~BIOMarkers of Ependymomas in Children and~~
Adolescents (BIOMECA) - Integrated Biological study
within SIOP Ependymoma II trial organised by European
Ependymoma BiologyConsortium		 - 300 - (300) -
Advanced magnetic resonance imaging techniques for in
vivo assessment of tumour heterogeneity, risk factor, and
treatment response inpaediatric cancer		 - 8,300 - (8,300) -
Evaluation of B7H3 as a novel target for immunotherapy in
childhood cancer		 - 2,560 - (2,560) -
Dr Karin Straathof, UCL Institute of Child Health,
Development of GD2-specific Bi-specific T-cell Engagers
(BiTEs)for treatment of neuroblastoma		 - 9,500 - (9,500) -
Professor Christine Harrison, Northern Institute for Cancer
Research, Newcastle University, Sequencing the
unsequenceable: development of ground-breaking
technologies to investigate the role of complex genomic
sequences in childhood cancer		 - 56,108 - (56,108) -
Helen E Bryant, University of Sheffield, Novel therapies for
MYCN-amplified neuroblastoma		 - 500 - (500) -
~~Dr Amin Hajitou, Imperial College London, Investigation of~~
a harmless prokaryotic virus for intravenous targeting
deliveryof therapeutic nucleic acids to DIPG		 - 25,000 - (25,000) -
Professor Louis Chesler, Institute for Cancer Research-
Individualising Management of Paediatric Cancer
Treatment - IMPACT		 - 49,188 - (49,188) -
Professor Sibylle Mittnacht, UCL Cancer Institute-
Exploring retinoblastoma protein loss as an actionable
target inpaediatric bone and soft tissue sarcoma		 - 750 - (750) -
Dr John Bithell, University of Oxford- Preservation and
analysis of pathology records and family histories of
children with cancer		 - 500 - (500) -

71

Financial Statements

For the year ended 31 December 2020

Year ended 31 December 2019 At the start
of the year
£		 Total
Income
£		 Total
Expenditure
£		 Transfers &
Investment
gains/losses
£		 At the end
of the year
£
Clinical PHD Studentship: Markers of Hypothalamic
Dysfunction in Children with Hypothalamo-Pituitary-Axis
Tumours(HPAT)or PituitaryMaldevelopment		 - 75 - (75) -
Osteosarcoma Symposium - 30,000 (30,000) - -
Functions of DOT1L and H3K79 methylation in MLL-
rearranged leukaemia		 - 11,753 (11,753) - -
Beads of Courage UK, which helps children in all 110
children’s cancer wards in the UK visualise and articulate
their cancerjourney		 - 50,238 (50.238) - -
Children’s Leukaemia Trust. Restricted for research into
and trainingfor Leukaemia and Lymphoma in children		 1,064,478 (7,177) (529,957) - 527,344
__ __ __ __ __
Total Restricted funds 1,064,478 240,594 (621,947) (155,781) 527,344
Unrestricted funds 9,107,144 17,089,346 (16,195,000) 372,449 10,373,939
__ __ __ __ __
Total Unrestricted funds 9,107,144 17,089,346 (16,195,000) 372,449 10,373,939
Total funds 10,171,622 17,329,940 (16,816,947) 216,668 10,901,283
======== ======== ======== ======== ========

20. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

A management fee of £5,000 (2019: £5,000) has been charged to the trading subsidiary for use of the charity’s trademarks and a further £3,645 (2019: £3,484) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2020, £41,369 (2019: £41,006) owed to the charity from the trading subsidiary.

21. Financial Instruments

The financial statements include the following in respect of items:

2020
£		 2019
£
~~Financial assets measured at fair value~~ ~~1,778,177~~ ~~1,803,668~~
2020
£		 2019
£
~~The entity’s income, expense, gains and losses in respect of~~
financial instruments are summarised below:
Total interest income for financial assets held at fair value 129,182 82,499

72

Financial Statements For the year ended 31 December 2020

22. Grants to third parties

22. Grants to third parties
Research
into
prevention
and causes
2020
£		 Research
into
treatment
2020
£		 Raising
Awareness
2020
£		 Welfare
2020
£		 Total 2020
£
Cancer Research UK–Children with Cancer UK Innovation
Awards		 1,295,725 1,204,275 2,500,000
Teenage Cancer Trust: Emergency Coronavirus Appeal 1,000,000 1,000,000
Mike Hawkins - University of Birmingham - Establish a
comprehensive surveillance system for adverse health
outcomes in British survivors of childhood, teenage and young
adult cancer		 349,982 349,982
Kathy Pritchard-Jones - UCL Great Ormond Street Institute of
Child Health - International benchmarking of childhood cancer
survival bystage		 349,747 349,747
Chris Jones - Institute of Cancer Research - Evolutionary
dynamics of MEK inhibitor sensitivity and resistance in diffuse
midlineglioma		 349,393 349,393
Steve Clifford - Newcastle University - SMILE: An
International network for Medulloblastoma Survivorship and
Late-Effects		 348,783 348,783
Sam Behjati - Wellcome Sanger Institute - Developmental
states of localised and metastatic osteosarcoma cells – a
knowledge bank for novel biomarkers and therapeutic
approaches		 349,419 349,419
Beads of Courage - 2020 285,296 285,296
~~Anthony Chalmers - University of Glasgow - Increasing the~~
susceptibility of neuroblastoma cells to radiotherapy by
targeting glycolysis and lipogenesis		 249,774 249,774
~~Veronica Kinsler - UCL Great Ormond Street Institute of Child~~
Health - Identification of new therapies for melanoma in
congenital melanocytic naevi - a universally fatal paediatric
tumour		 249,756 249,756
Marc Mansour - UCL Cancer Institute - CCR9 as a novel
immunotherapy target in T-cell acute lymphoblastic leukaemia
(T-ALL)		 249,325 249,325
Macarena Oporto Espuelas - UCL Great Ormond Street
Institute of Child Health - Identification of novel surface antigen
targets for CAR T cell strategies in paediatric Acute Myeloid
Leukaemia stem cells.		 220,000 220,000
Defne Saatci - UCL Great Ormond Street Institute of Child
Health - Investigating Late Effects of Surviving Childhood
Cancer		 216,963 216,963
Julie Irving - Newcastle University - Optimising the use of
repurposed drugs to improve the treatment of children with
ALL		 213,259 213,259
Schuz - International Agency for Research on Cancer - Dr
Joachim Schüz, CLIC Data CoordinatingCenter - Extension		 95,060 95,060
International Agency for Research on Cancers - IARC
Postdoctoral Fellowship		 81,933 81,933
~~Ian Fairlie - NA - Report: The effects of Low Level Ionising~~
Radiation Exposure especially regarding child and young
person cancer incidence		 78,588 78,588
~~Chris Jones - Institute of Cancer Research - INSTINCT interim~~
funding		 10,000 58,380 68,380
Claire Clarkin - University of Southampton - Developing 3-
dimensional multicellular models of osteosarcoma		 49,984 49,984
John Anderson - UCL Great Ormond Street Institute of Child
Health - Pilot to developCRISPR library screen for enhanced
function of G-D-T cells inpaediatric solid cancers.		 49,930 49,930
Faith Gibson - University of Surrey - PersonAlised
survivorship care: customising supporT towards unmet
psycHosocial needs inyoung people with cancer(PATH study)		 48,202 48,202
Steve Clifford - Newcastle University - INSTINCT interim
funding		 21,316 21,316
BCRT - Bone Cancer Research Trust - 20,000 20,000

73

Financial Statements

For the year ended 31 December 2020

Research
into
prevention
and causes
2020
£		 Research
into
treatment
2020
£		 Raising
Awareness
2020
£		 Welfare
2020
£		 Total 2020
£
John Murphy - University of Westminster - A pilot Investigation
of the ZFP36L1 protein as a candidate therapeutic target in
osteosarcoma cells		 14,013 14,013
International Agency for Research on Cancers - IARC
Postdoctoral Fellowship		 5,154 5,154
~~Raoul Reulen - University of Birmingham - Pilot study to~~
investigate self-reported health behaviours in survivors of
teenage andyoungadult cancer		 5,000 5,000
~~M Niklison - Queen Mary University of London - Paul~~
O’Gorman Post-doctoral Research Fellowship - Metabolic
analysis of the tumour suppressor protein p73 in
medulloblastoma		 3,812 3,812
Becci Pearson - British Neuro-Oncology Society - BNOS
Sponsorship		 750 750
Total grants to third parties awarded in the year 1,570,272 4,597,501 20,750 1,285,296 7,473,819
Underspends on previous grant awards
Tariq Enver - UCL Cancer Institute - Dissecting the causative
and collaborating roles of candidate genetic mutations in the
pathogenesis of childhood ALL		 (293) (293)
Dr Steven Pollard, University of Edinburgh. Genome editing of
human neural stem cells using nuclease-assisted gene
targeting: a tool to uncover the function of H3F3A mutations in
paediatricglioma		 (455) (455)
Waseem Qasim - UCL Great Ormond Street Institute of Child
Health - T cell receptor gene therapy: Novel strategies for
children with cancer usingengineered cord blood T cells		 (788) (788)
Professor Chris Jones, Institute of Cancer Research, The role
of histone H4K20 methylation in paediatric glioblastoma and
DIPG		 (2,648) (2,648)
Dr Marc Tischkowitz, University of Cambridge, Investigating
microRNA processing genes in rhabdomyosarcomas and other
DICER1-related childhood tumours		 (2,661) (2,661)
Professor Robert Mairs, University of Glasgow. Exploitation of
the elevated metabolic activity of cancer cells for combination
with targeted radiotherapyof neuroblastoma		 (4,997) (4,997)
Dr Suzanne Turner, University of Cambridge, CRISPR-based
genome-wide knockout and overexpression screens to identify
acquired resistance mechanisms to ALK inhibition in
neuroblastoma		 (6,511) (6,511)
Dr Faith Gibson - Great Ormond Street Hospital - Evaluating
HELP: an intervention for parents sharing information about
leukaemia with their child.		 (13,999) (13,999)
Katherine Clesham - UCL Great Ormond Street Institute of
Child Health - Targeting c-MYB in acute leukaemia through
drugrepositioning		 (18,722) (18,722)
Immunotherapy with CD19ζ gene-modified EBV-specific CTLs
after stem cell transplantation in children with high-risk acute
lymphoblastic leukaemia		 (22,420) (22,420)
Dr Elizabeth Calton, The Institute of Cancer Research,
Mutational dynamics and their effect on chemoresistance and
metastasis in a genetically engineered mouse model of
relapsed neuroblastoma		 (25,777) (25,777)
Dr Patrick Hales, Institute of Child Health, University College
London. Advanced magnetic resonance imaging techniques
for in vivo assessment of tumour heterogeneity, risk factor, and
treatment response inpaediatric cancer		 (115,379) (115,379)
Professor Pamela Kearns. Programme grant: UK ALL 2011 (272,408) (272,408)
Total grants to third parties 1,564,215 4,130,499 6,751 1,285,296 6,986,761

74

Financial Statements For the year ended 31 December 2020

Every day more than 12 children and young people are diagnosed with cancer in the UK.

8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.

We need to develop safer, kinder and more effective cancer therapies for children, with fewer toxic side effects. We strive to ensure that we are doing everything we can to improve the lives of children with cancer.

We fund Research We fund Welfare We raise Awareness

Children with Cancer UK Registered Office 51 Great Ormond Street London WC1N 3JQ

75